Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 57
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Proteomics Characterization of Clear Cell Renal Cell Carcinoma

  • Miranda Poma, Jesús
  • Trilla Fuertes, Lucía
  • López Vacas, Rocío
  • López Camacho, Elena
  • García Fernández, Eugenia
  • Pertejo, Ana
  • Lumbreras Herrera, María I.
  • Zapater Moros, Andrea
  • Díaz Almirón, Mariana
  • Dittmann, Antje
  • Fresno Vara, Juan Ángel
  • Espinosa Arranz, Enrique
  • González-Peramato Gutiérrez, María del Pilar
  • Pinto Marín, Álvaro
  • Gámez Pozo, Angelo
Purpose: To explore the tumor proteome of patients diagnosed with localized clear cell renal cancer (ccRCC) and treated with surgery. Material and methods: A total of 165 FFPE tumor samples from patients diagnosed with ccRCC were analyzed using DIA-proteomics. Proteomics ccRCC subtypes were defined using a consensus cluster algorithm (CCA) and characterized by a functional approach using probabilistic graphical models and survival analyses. Results: We identified and quantified 3091 proteins, including 2026 high-confidence proteins. Two proteomics subtypes of ccRCC (CC1 and CC2) were identified by CC using the high-confidence proteins only. Characterization of molecular differences between CC1 and CC2 was performed in two steps. First, we defined 514 proteins showing differential expression between the two subtypes using a significance analysis of microarrays analysis. Proteins overexpressed in CC1 were mainly related to translation and ribosome, while proteins overexpressed in CC2 were mainly related to focal adhesion and membrane. Second, a functional analysis using probabilistic graphical models was performed. CC1 subtype is characterized by an increased expression of proteins related to glycolysis, mitochondria, translation, adhesion proteins related to cytoskeleton and actin, nucleosome, and spliceosome, while CC2 subtype showed higher expression of proteins involved in focal adhesion, extracellular matrix, and collagen organization. Conclusions: ccRCC tumors can be classified in two different proteomics subtypes. CC1 and CC2 present specific proteomics profiles, reflecting alterations of different molecular pathways in each subtype. The knowledge generated in this type of studies could help in the development of new drugs targeting subtype-specific deregulated pathways, This work was supported by EPIC-XS, project number 823839, funded by the Horizon 2020 program of the European Union. María I. Lumbreras-Herrera and Andrea Zapater Moros are supported by Consejería de Educación e Investigación de la Comunidad de Madrid (IND2018/BMD9262). Elena López Camacho is supported by the Spanish Economy and Competitiveness Ministry (PTQ2018-009760). The funding agencies had no role in the design of this study, its execution or analyses, the interpretation of the data, or the decision to submit the results
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Functional proteomics of colon cancer Consensus Molecular Subtypes

  • Feliú Batlle, Jaime
  • Gámez Pozo, Angelo
  • Martínez Pérez, Daniel
  • Pérez Wert, Pablo
  • Matamala Luengo, Daniel
  • Viñal, David
  • Kunz, Laura
  • López Vacas, Rocío
  • Dittmann, Antje
  • Rodríguez Salas, Nuria
  • Custodio, Ana
  • Fresno Vara, Juan Ángel
  • Trilla Fuertes, Lucía
Background The Colorectal Cancer Subtyping Consortium established four Consensus Molecular Subtypes (CMS) in colorectal cancer: CMS1 (microsatellite-instability [MSI], Immune), CMS2 (Canonical, epithelial), CMS3 (Metabolic), and CMS4 (Mesenchymal). However, only MSI tumour patients have seen a change in their disease management in clinical practice. This study aims to characterise the proteome of colon cancer CMS and broaden CMS’s clinical utility. Methods One-hundred fifty-eight paraffin samples from stage II-III colon cancer patients treated with adjuvant chemotherapy were analysed through DIA-based mass-spectrometry proteomics. Results CMS1 exhibited overexpression of immune-related proteins, specifically related to neutrophils, phagocytosis, antimicrobial response, and a glycolytic profile. These findings suggested potential therapeutic strategies involving immunotherapy and glycolytic inhibitors. CMS3 showed overexpression of metabolic proteins. CMS2 displayed a heterogeneous protein profile. Notably, two proteomics subtypes within CMS2, with different protein characteristics and prognoses, were identified. CMS4 emerged as the most distinct group, featuring overexpression of proteins related to angiogenesis, extracellular matrix, focal adhesion, and complement activation. CMS4 showed a high metastatic profile and suggested possible chemoresistance that may explain its worse prognosis. Conclusions DIA proteomics revealed new features for each colon cancer CMS subtype. These findings provide valuable insights into potential therapeutic targets for colorectal cancer subtypes in the future, This work was supported by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma

  • Trilla Fuertes, Lucía
  • Gámez Pozo, Angelo
  • Nogué, Miguel
  • Busquier, Isabel
  • Arias, Fernando
  • López Campos, Fernando
  • Fernández Montes, Ana
  • Ruiz, Ana
  • Velázquez, Concepción
  • Martín Bravo, Celia
  • Pérez Ruiz, Elisabeth
  • Asensio, Elena
  • Hernández Yagüe, Xavier
  • Rodrigues, Aline
  • Ghanem, Ismael
  • López Vacas, Rocío
  • Hafez, Ahmed
  • Arias, Pedro
  • Dapía, Irene
  • Solís, Mario
  • Dittmann, Antje
  • Ramos, Ricardo
  • Llorens, Carlos
  • Maurel, Joan
  • Campos Barros, Ángel
  • Fresno Vara, Juan Ángel
  • Feliú Batlle, Jaime
Background: Anal squamous cell carcinoma (ASCC) is an infrequent tumor whose treatment has not changed since the 1970s. The aim of this study is the identification of biomarkers allowing personalized treatments and improvement of therapeutic outcomes. Methods: Forty-six paraffin tumor samples from ASCC patients were analyzed by whole-exome sequencing. Copy number variants (CNVs) were identified and their relation to disease-free survival (DFS) was studied and validated in an independent retrospective cohort of 101 ASCC patients from the Multidisciplinary Spanish Digestive Cancer Group (GEMCAD). GEMCAD cohort proteomics allowed assessing the biological features of these tumors. Results: On the discovery cohort, the median age was 61 years old, 50% were males, stages I/II/III: 3 (7%)/16 (35%)/27 (58%), respectively, median DFS was 33 months, and overall survival was 45 months. Twenty-nine genes whose duplication was related to DFS were identified. The most representative was duplications of the CYP2D locus, including CYP2D6, CYP2D7P, and CYP2D8P genes. Patients with CYP2D6 CNV had worse DFS at 5 years than those with two CYP2D6 copies (21% vs. 84%; p <.0002, hazard ratio [HR], 5.8; 95% confidence interval [CI], 2.7–24.9). In the GEMCAD validation cohort, patients with CYP2D6 CNV also had worse DFS at 5 years (56% vs. 87%; p =.02, HR = 3.6; 95% CI, 1.1–5.7). Mitochondria and mitochondrial cell-cycle proteins were overexpressed in patients with CYP2D6 CNV. Conclusions: Tumor CYP2D6 CNV identified patients with a significantly worse DFS at 5 years among localized ASCC patients treated with 5-fluorouracil, mitomycin C, and radiotherapy. Proteomics pointed out mitochondria and mitochondrial cell-cycle genes as possible therapeutic targets for these high-risk patients. Plain Language Summary: Anal squamous cell carcinoma is an infrequent tumor whose treatment has not been changed since the 1970s. However, disease-free survival in late staged tumors is between 40% and 70%. The presence of an alteration in the number of copies of CYP2D6 gene is a biomarker of worse disease-free survival. The analysis of the proteins in these high-risk patients pointed out mitochondria and mitochondrial cell-cycle genes as possible therapeutic targets. Therefore, the determination of the number of copies of CYP2D6 allows the identification of anal squamous carcinoma patients with a high-risk of relapse that could be redirected to a clinical trial. Additionally, this study may be useful to suggest new treatment strategies to increase current therapy efficacy, IdiPAZ, Grant/Award Number: Jesús Antolín Garciarena Fellowship; European Proteomics Infrastructure Consortium, Grant/Award Number: 823839, Horizon 2020 Programme
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Identification of carcinogenesis and tumor progression processes in pancreatic ductal adenocarcinoma using high-throughput proteomics

  • Trilla Fuertes, Lucía
  • Gámez Pozo, Angelo
  • Lumbreras-Herrera, María Isabel
  • López-Vacas, Rocío
  • Heredia-Soto, Victoria
  • Ghanem, Ismael
  • López-Camacho, Elena
  • Zapater-Moros, Andrea
  • Miguel, María
  • Pena Burgos, Eva Manuela
  • Palacios, Elena
  • de Uribe, Marta
  • Guerra, Laura
  • Dittmann, Antje
  • Mendiola, Marta
  • Vara, Juan Ángel Fresno
  • Feliú Batlle, Jaime
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with an overall 5-year survival rate of just 5%. A better understanding of the carcinogenesis processes and the mechanisms of the progression of PDAC is mandatory. Fifty-two PDAC patients treated with surgery and adjuvant therapy, with available primary tumors, normal tissue, preneoplastic lesions (PanIN), and/or lymph node metastases, were selected for the study. Proteins were extracted from small punches and analyzed by LC-MS/MS using data-independent acquisition. Proteomics data were analyzed using probabilistic graphical models, allowing functional characterization. Comparisons between groups were made using linear mixed models. Three proteomic tumor subtypes were defined. T1 (32% of patients) was related to adhesion, T2 (34%) had metabolic features, and T3 (34%) presented high splicing and nucleoplasm activity. These proteomics subtypes were validated in the PDAC TCGA cohort. Relevant biological processes related to carcinogenesis and tumor progression were studied in each subtype. Carcinogenesis in the T1 subtype seems to be related to an increase of adhesion and complement activation node activity, whereas tumor progression seems to be related to nucleoplasm and translation nodes. Regarding the T2 subtype, it seems that metabolism and, especially, mitochondria act as the motor of cancer development. T3 analyses point out that nucleoplasm, mitochondria and metabolism, and extracellular matrix nodes could be involved in T3 tumor carcinogenesis. The identified processes were different among proteomics subtypes, suggesting that the molecular motor of the disease is different in each subtype. These differences can have implications for the development of future tailored therapeutic approaches for each PDAC proteomics subtype, This research was funded by EPIC-XS, project number 823839, the Horizon 2020 programme of the European Union, and ISCIII PI18/01604
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Goat milk exosomes as natural nanoparticles for detecting inflammatory processes by optical imaging

  • Santos Coquillat, Ana
  • González, María Isabel
  • Clemente Moragon, Agustin
  • González Arjona, Mario
  • Albaladejo García, Virginia
  • Peinado, Héctor
  • Muñoz, Javier
  • Ximenez Embun, Pilar
  • Ibáñez, Borja
  • Oliver, Eduardo
  • Desco Menéndez, Manuel
  • Salinas Rodríguez, Beatriz
Exosomes are cell-derived nanovesicles with a proven intercellular signaling role in inflammation processes and immune response. Due to their natural origin and liposome-like structure, these nanometer-scale vesicles have emerged as novel platforms for therapy and diagnosis. In this work, goat milk exosomes are isolated and fully characterized in terms of their physicochemical properties, proteomics, and biochemical profile in healthy mice, and used to detect inflammatory processes by optical imaging. For the in vitro and in vivo experiments, the exosomes are covalently labeled with the commercial fluorophores sulfo-Cyanine 5 and BODIPY-FL to create nanoprobes. In vitro studies using confocal imaging, flow cytometry, and colorimetric assays confirm the internalization of the nanoprobes as well their lack of cytotoxicity in macrophage populations RAW 264.7. Optical imaging in the mouse peritoneal region confirms the in vivo ability of one of the nanoprobes to localize inflammatory processes. In vivo imaging shows exosome uptake in the inflamed peritoneal region, and flow-cytometric analysis of peritonitis exudates confirms the uptake by macrophage and neutrophil populations. These results support the promising use of goat milk exosomes as natural probes in the detection of inflammatory processes., This study has been funded by Instituto de Salud Carlos III, through the project "PI20/01632", co-funded by European Regional Development Fund (ERDF), "A way to make Europe" and by Comunidad de Madrid, project "Y2018/NMT-4949 (NanoLiver-CM)" and "S2017/BMD-3867 (RENIM-CM)", co-funded by European Structural and Investment Fund. This work has been also supported by "Diagnosis and treatment follow-up of severe Staphylococcal Infections with Anti-Staphylococcal antibodies and Immune-PET - Grant Fundación BBVA a Equipos de Investigación Científica 2018". A. Santos-Coquillat is grateful for financial support to Consejería de Educación e Investigación, co-financed by European Social Fund (ESF) grant PEJD-2018-POST/BMD-9592. A. Santos Coquillat is also funded by Instituto de Salud Carlos III, co-funded by European Social Fund "Investing in your future" (grant CD19/00136). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation. The CNIO Proteomics Unit is funded by the H2020 project EPIC-XS (ref. 823839). Biomedical Imaging has been conducted at the Advanced Imaging Unit of the CNIC (Centro Nacional de Investigaciones Cardiovasculares Carlos III), Madrid, Spain.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Use of linear ion traps in data-independent acquisition methods benefits low-input proteomics

  • Borràs, Eva
  • Pastor, Olga
  • Sabidó Aguadé, Eduard, 1981-
The need for a better understanding of cellular heterogeneity has pushed mass spectrometry technologies to the analysis of single-cell and single-cell-type proteomes, although several challenges still limit their widespread implementation. Among the efforts toward single-cell and low-input analyses, there is the adoption of data-independent acquisition methods to increase analytical sensitivity. Here, we revisited the use of linear ion traps mass analyzers in data-independent acquisition methods and demonstrate their benefits to boost peptide and protein identifications in low-input proteomes., Funding: the CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is member of ProteoRed PRB3 consortium which is supported by Grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII), ERDF, and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). This project was supported by EPIC-XS, Project Number 823839, funded by the Horizon 2020 programme of the European Union. We also acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

QCloud2: an improved cloud-based quality-control system for mass-spectrometry-based proteomics laboratories

  • Olivella, Roger
  • Chiva, Cristina
  • Serret, Marc
  • Mancera, Daniel
  • Cozzuto, Luca
  • Hermoso Pulido, Antonio
  • Borràs, Eva
  • Espadas, Guadalupe
  • Morales Sanfrutos, Julia
  • Pastor, Olga
  • Solé, Amanda
  • Ponomarenko, Julia
  • Sabidó Aguadé, Eduard, 1981-
QCloud is a cloud-based system to support proteomics laboratories in daily quality assessment using a user-friendly interface, easy setup, and automated data processing. Since its release, QCloud has facilitated automated quality control for proteomics experiments in many laboratories. QCloud provides a quick and effortless evaluation of instrument performance that helps to overcome many analytical challenges derived from clinical and translational research. Here we present an improved version of the system, QCloud2. This new version includes enhancements in the scalability and reproducibility of the quality-control pipelines, and it features an improved front end for data visualization, user management, and chart annotation. The QCloud2 system also includes programmatic access and a standalone local version., The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is a member of the ProteoRed PRB3 consortium, which is supported by grant PT17/0019 of the PE I+D+i 2013−2016 from the Instituto de Salud Carlos III (ISCIII), ERDF, and “Secretaria d’Universitats i Recerca del Departament d’Econòmia i Coneixement de la Generalitat de Catalunya” (2017SGR595). This project was supported by EPIC-XS, project number 823839, funded by the Horizon 2020 Programme of the European Union. We also acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme from Generalitat de Catalunya
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

PDBe-KB: collaboratively defining the biological context of structural data

  • Varadi, Mihaly
  • Radusky, Leandro
  • Serrano Pubull, Luis, 1982-
  • Velankar, Sameer
  • PDBe-KB consortium
The Protein Data Bank in Europe - Knowledge Base (PDBe-KB, https://pdbe-kb.org) is an open collaboration between world-leading specialist data resources contributing functional and biophysical annotations derived from or relevant to the Protein Data Bank (PDB). The goal of PDBe-KB is to place macromolecular structure data in their biological context by developing standardised data exchange formats and integrating functional annotations from the contributing partner resources into a knowledge graph that can provide valuable biological insights. Since we described PDBe-KB in 2019, there have been significant improvements in the variety of available annotation data sets and user functionality. Here, we provide an overview of the consortium, highlighting the addition of annotations such as predicted covalent binders, phosphorylation sites, effects of mutations on the protein structure and energetic local frustration. In addition, we describe a library of reusable web-based visualisation components and introduce new features such as a bulk download data service and a novel superposition service that generates clusters of superposed protein chains weekly for the whole PDB archive., Funding: ELIXIR [IDP implementation study]; Biotechnology and Biological Sciences Research Council via the 3D-Gateway [BB/T01959X/1]; FunPDBe [BB/P024351/1]; J.D. acknowledges support from the Ministry of Education, Youth and Sport of the Czech Republic [INBIO CZ.02.1.01/0.0/0.0/16_026/0008451]; R.S., K.B. and J.D. also acknowledge support from the Ministry of Education, Youth and Sport of the Czech Republic [ELIXIR-CZ LM2018131]; L.M. acknowledges support from the European Union's Horizon 2020 Programme (H2020-INFRAIA-2018-1) [823839]; Research Foundation Flanders (FWO) [G032816N, G042518N, G028821N]; W.V. acknowledges support from the Research Foundation Flanders (FWO) [G032816N, G028821N]; A.R. acknowledges support from the Fondazione Cassa Di Risparmio di Firenze [24316]; European Commission [101017567]; M.H.C. acknowledges the AIRC project to MHC [IG 23539]; J.F.-R. acknowledges support from the Spanish Ministry of Science and Innovation [PID2019-110167RB-I00]; N.R. acknowledges support from the Norwegian Research Council (Norges Forskningsråd) [288008]; E.D.L. acknowledges support from the European Union's Horizon 2020 research and innovation programme [819318]; M.J.E.S. acknowledges support from the Wellcome Trust [104955/Z/14/Z, 218242/Z/19/Z]. Funding for open access charge: Biotechnology and Biological Sciences Research Council grant [BB/T01959X/1]; Wellcome Trust [104955/Z/14/Z and 218242/Z/19/Z]
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

MassIVE.quant: a community resource of quantitative mass spectrometry-based proteomics datasets

  • Choi, Meena
  • Chiva, Cristina
  • Sabidó Aguadé, Eduard, 1981-
  • Vitek, Olga
MassIVE.quant is a repository infrastructure and data resource for reproducible quantitative mass spectrometry-based proteomics, which is compatible with all mass spectrometry data acquisition types and computational analysis tools. A branch structure enables MassIVE.quant to systematically store raw experimental data, metadata of the experimental design, scripts of the quantitative analysis workflow, intermediate input and output files, as well as alternative reanalyses of the same dataset., This work was supported in part by NSF CAREER award no. DBI-1054826, grant no. NSF DBI-1759736 and the Chan-Zuckerberg foundation to O.V., grant no. NIH-NLM 1R01LM013115 to N.B. and O.V., NSF award no. ABI 1759980, NIH award nos. P41GM103484 and R24GM127667 to N.B. and the Personalized Health and Related Technologies (grant no. PHRT 0-21411-18) strategic focus area of ETH to B.W. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium that is supported by grant no. PT17/0019 of the PE I+D+i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, ‘Centro de Excelencia Severo Ochoa 2013–2017’, SEV-2012–0208 and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya (grant no. 2017SGR595). This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 823839 (EPIC-XS). Y.P.-R. acknowledges the Wellcome Trust (grant no. 208391/Z/17/Z).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Quality standards in proteomics research facilities: Common standards and quality procedures are essential for proteomics facilities and their users

  • Chiva, Cristina
  • Mendes Maja, Teresa
  • Panse, Christian
  • Stejskal, Karel
  • Douché, Thibaut
  • Matondo, Mariette
  • Loew, Damarys
  • Helm, Dominic
  • Rettel, Mandy
  • Mechtler, Karl
  • Impens, Francis
  • Nanni, Paolo
  • Shevchenko, Anna
  • Sabidó Aguadé, Eduard, 1981-
Proteomics research infrastructures and core facilities within the Core for Life alliance advocate for community policies for quality control to ensure high standards in proteomics services., The CRG/UPF Proteomics Unit is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D+i 2013‐2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, “Centro de Excelencia Severo Ochoa 2013‐2017”, SEV‐2012‐ 0208, and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The VIB Proteomics Core acknowledges support from the VIB Tech Watch Fund and FWO‐SBO Project S006617N. Research in the Mechtler lab was supported by the ERA‐CAPS I 3686 project of the Austrian Science Fund. We acknowledge support from the European Union's Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC‐XS)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Rogalska, Malgorzata
  • Valcárcel, J. (Juan)
  • Carracedo, Arkaitz
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dissecting sexual dimorphism in aortic valve stenosis by proteomics

  • Grego, Ana
  • Sousa-Mendes, Cláudia
  • Martins, Diana
  • Sousa, Carla
  • Ferreira, Ana Filipa
  • Saraiva, Francisca
  • Alves, Inês
  • Espadas, Guadalupe
  • Miranda, Isabel
  • Leite-Moreira, Adelino
  • Sabidó Aguadé, Eduard, 1981-
  • Barros, António S.
  • Gavina, Cristina
  • Vitorino, Rui
  • Falcão-Pires, Inês
  • Nogueira-Ferreira, Rita
  • Trindade, Fábio
Background: The treatment of aortic valve stenosis (AVS) remains limited to aortic valve replacement (AVR). No pharmacotherapy has yet proven efficacious, and its development is challenged by sexual dimorphism. Women display extensive valve fibrosis, and men present remarkably higher valve calcification. To accelerate the development of sex-personalised therapies, deeper molecular insights are needed. Hence, we aimed to characterise AVS sexual dimorphism using proteomics. Methods: Fifty surgically excised valves (50% women) were homogenised, and the proteins were quantified by LC-MS/MS. The influence of differentially expressed proteins (DEPs) in sexual dimorphism was appraised using bioinformatics. DEPs were validated using immunohistochemistry, qRT-PCR and ELISA, with 30 additional valves. Results: We quantified ~ 4,000 proteins and 76 DEPs between sexes. CD163, CD74, and NADPH oxidase-2 (NOX2) were more abundant in men's valves and central in a protein-protein interaction network. Functional enrichment analysis (FEA) supported increased lipoprotein binding and macrophage activation in men's valves, confirmed by increased CD74 + cell infiltration (immunohistochemistry). Aminopeptidase N, coagulation factor XIII, and metalloreductase STEAP4 were more abundant in men's valves at the transcript and protein levels. FEA indicated a women-specific dysregulation of spliceosomal proteins that may dictate a pro-fibrotic phenotype, which was observed histologically. A higher glutathione peroxidase-1/NOX2 ratio (ELISA) was found in women, suggesting increased protection against oxidative stress. Conclusions: Proteomics confirms sexual dimorphism in AVS. Women displayed a higher degree of fibrotic remodelling, whereas men displayed greater immune cell infiltration and were less protected from oxidation, favouring calcification. Proteomics identified putative targets for a sex-personalised AVS modulation., This work was supported by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union; Sigma Xi, The Scientific Research Honor Society (NC, USA), grant number G20230315-4761, and by national funds through FCT (Fundação para a Ciência e a Tecnologia, I.P.), within the scope of the Cardiovascular R&D Center (UIDB/00051/2020, UIDP/00051/2020) and RISE (LA/P/0053/2020). A.G. was supported by a fellowship grant from the SEXDIFEND project (2022.04344.PTDC, https://doi.org/10.54499/2022.04344.PTDC). I.A. and D.M. are supported by doctoral fellowships by FCT (grants 2022.11324.BD and 2021.06947.BD, respectively). R.N.F. is supported by FCT through the research contract CEECIND/03935/2021 under the CEEC Individual 2021 (https://doi.org/10.54499/2021.03935.CEECIND/CP1685/CT0001). F.T. was supported by a postdoctoral research grant from FCT through the Cardiovascular R&D Centre (UnIC, UIDP/00051/2020). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). G.E. and E.S. are supported by the Spanish Ministry of Science and Innovation (“Centro de Excelencia Severo Ochoa 2013–2017”, SEV-2012-0208), and by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2021SGR01225). G.E. and E.S. are also supported by the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Programme from Generalitat de Catalunya.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Chromatin-bound proteome profiling by genome capture

  • Aranda Aragón, Sergio
  • Borràs, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Di Croce, Luciano
De novo identification of chromatin interactors can reveal unexpected pathways relevant to physiology and human disease. Inspired by the DNA mediated chromatin pull-down (Dm-ChP) technology (also known as iPOND [isolation of proteins on nascent DNA]) for the proteomic characterization of nascent DNA, we have recently reported a new experimental protocol that allows for the identification of proteins on total DNA (iPOTD) for bulk chromatome profiling and de novo identification of chromatin-bound proteins. Here, we detail a step-by-step protocol to survey the cellular chromatin-bound proteome in a simple, robust, and unbiased manner. For complete details on the use and execution of this protocol, please refer to Aranda et al. (2019)., The Proteomics Unit is supported by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union. The Di Croce Laboratory is supported by grants from the Spanish Ministerio de Educación y Ciencia (BFU2016-75008-P) and by AGAUR.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling

  • Bradbury Lobato, Melissa, 1983-
  • Borràs, Eva
  • Castellví, Josep
  • Méndez, Olga
  • Sánchez-Iglesias, José Luis
  • Pérez-Benavente, Assumpció
  • Gil-Moreno, Antonio
  • Sabidó Aguadé, Eduard, 1981-
  • Santamaria, Anna
Despite recent advances in the management of BRCA1 mutated high-grade serous ovarian cancer (HGSC), the physiology of these tumors remains poorly understood. Here we provide a comprehensive molecular understanding of the signaling processes that drive HGSC pathogenesis with the addition of valuable ubiquitination profiling, and their dependency on BRCA1 mutation-state directly in patient-derived tissues. Using a multilayered proteomic approach, we show the tight coordination between the ubiquitination and phosphorylation regulatory layers and their role in key cellular processes related to BRCA1-dependent HGSC pathogenesis. In addition, we identify key bridging proteins, kinase activity, and post-translational modifications responsible for molding distinct cancer phenotypes, thus providing new opportunities for therapeutic intervention, and ultimately advance towards a more personalized patient care., This work was supported by the PhD4MD collaborative research program between the Vall d’Hebron Research Institute (VHIR) and the Centre for Genomic Regulation (CRG). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, (CTQ2016-80364-P and “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208), and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595 and 2017SGR1661). This project has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC-XS). It has also been supported by grants from the Instituto Carlos III (PI15/00238, PI18/01017, PI21/00977), the Miguel Servet Program (CP13/00158 and CPII18/00027) and the Ministerio de Economía y Competitividad y Fondos FEDER (RTC-2015-3821-1)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Beauveria bassiana rewires molecular mechanisms related to growth and defense in tomato

  • Proietti, Silvia
  • Falconieri, Gaia Salvatore
  • Bertini, Laura
  • Pascale, Alberto
  • Bizzarri, Elisabetta
  • Morales Sanfrutos, Julia
  • Sabidó Aguadé, Eduard, 1981-
  • Ruocco, Michelina
  • Monti, Maurilia M.
  • Russo, Assunta
  • Dziurka, Kinga
  • Ceci, Marcello
  • Loreto, Francesco
  • Caruso, Carla
Plant roots can exploit beneficial associations with soil-inhabiting microbes, promoting growth and expanding the immune capacity of the host plant. In this work, we aimed to provide new information on changes occurring in tomato interacting with the beneficial fungus Beauveria bassiana. The tomato leaf proteome revealed perturbed molecular pathways during the establishment of the plant-fungus relationship. In the early stages of colonization (5-7 d), proteins related to defense responses to the fungus were down-regulated and proteins related to calcium transport were up-regulated. At later time points (12-19 d after colonization), up-regulation of molecular pathways linked to protein/amino acid turnover and to biosynthesis of energy compounds suggests beneficial interaction enhancing plant growth and development. At the later stage, the profile of leaf hormones and related compounds was also investigated, highlighting up-regulation of those related to plant growth and defense. Finally, B. bassiana colonization was found to improve plant resistance to Botrytis cinerea, impacting plant oxidative damage. Overall, our findings further expand current knowledge on the possible mechanisms underlying the beneficial role of B. bassiana in tomato plants., This work was supported by Ministero dell' Università e della Ricerca (MUR) - [PRIN Project no. 2017JLN833_005]: “Plant multitROphic interactions for bioinspired Strategies of PEst ConTrol (PROSPECT)”. The work of Alberto Pascale was supported by Marie Skłodowska‐Curie Individual Fellowship MSCA-IF-2019 [MetaFun, grant agreement: 893366]. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). This project was supported by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union. We also acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Programme/Generalitat de Catalunya, and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya (2017SGR595).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Claudin-6 mediates an embryonic stem cell-driven antitumor response against breast cancer

  • Correia, Magda
  • Tavares-Marcos, Carlota
  • Pessoa, João
  • Casanova, Miguel
  • Cavadas, Bruno
  • Vitorino, Rui
  • Tavares e Silva, Júlia
  • Mateus, Francisca
  • Espadas, Guadalupe
  • Pinheiro, Mariana
  • Alves-Vale, Catarina
  • Sabidó Aguadé, Eduard, 1981-
  • Neves, Bruno
  • Nóbrega-Pereira, Sandrina
  • Bernardes de Jesus, Bruno
Stem cells are emerging sources of antigens for cancer immunotherapy. Here, we used TNG-A mouse embryonic stem cells to trigger an anticancer response against tumors derived from E0771 mouse breast cancer cells, possibly mediated by the mouse immune system. TNG-A cells were cultured in the presence or absence of two specific kinase inhibitors. While the inhibitors preserved TNG-A pluripotency, their removal altered the morphology, transcriptome, and proteome of TNG-A cells, increasing their similarities with E0771 cancer cells. Double pre-exposure by subcutaneous injection of TNG-A cells followed by E0771 implantation drastically decreased E0771-derived tumor size in mice. Serum cytokine quantifications suggested a transient immune reaction associated with tumor regression. Nevertheless, pre-exposure to TNG-A cells impaired for the tight junction protein Claudin 6 failed to decrease tumor size. Our findings demonstrate the anti-tumor effects of embryonic stem cells and anticipate their potential as an allogenic source for cancer immunotherapy., This work was supported by Fundação para a Ciência e a Tecnologia (FCT) EXPL/BIA-CEL/0358/2021 and LISBOA-01-0145-FEDER-028534, project co-funded by the European Regional Development Fund (FEDER) through the POR Lisboa 2020—Programa Operacional Regional de Lisboa, Portugal 2020, and by FCT, through the project 2022.01199.PTDC DOI:10.54499/2022.01199. PTDC and Institute of Biomedicine—iBiMED (UIDP/04501/2020, UIDB/04501/2020 and UID 4501 - Institute of Biomedicine). B.C. is supported by the Junior Researcher grant CEECINST/00123/2021/CP1772/CT0001. S.N.-P. received funding from FCT CEECIND Program (2020.00355.CEECIND). M.C. was a recipient of an individual FCT predoctoral fellowship (UI/BD/151373/2021), Portugal. C.T.M. is funded by an individual predoctoral fellowship (BI/REIT/10332/2024), Portugal. This project has also received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC-XS). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Program/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Updated MS²PIP web server supports cutting-edge proteomics applications

  • Declercq, Arthur
  • Bouwmeester, Robbin
  • Chiva, Cristina
  • Sabidó Aguadé, Eduard, 1981-
  • Hirschler, Aurélie
  • Carapito, Christine
  • Martens, Lennart
  • Degroeve, Sven
  • Gabriels, Ralf
Interest in the use of machine learning for peptide fragmentation spectrum prediction has been strongly on the rise over the past years, especially for applications in challenging proteomics identification workflows such as immunopeptidomics and the full-proteome identification of data independent acquisition spectra. Since its inception, the MS²PIP peptide spectrum predictor has been widely used for various downstream applications, mostly thanks to its accuracy, ease-of-use, and broad applicability. We here present a thoroughly updated version of the MS²PIP web server, which includes new and more performant prediction models for both tryptic- and non-tryptic peptides, for immunopeptides, and for CID-fragmented TMT-labeled peptides. Additionally, we have also added new functionality to greatly facilitate the generation of proteome-wide predicted spectral libraries, requiring only a FASTA protein file as input. These libraries also include retention time predictions from DeepLC. Moreover, we now provide pre-built and ready-to-download spectral libraries for various model organisms in multiple DIA-compatible spectral library formats. Besides upgrading the back-end models, the user experience on the MS²PIP web server is thus also greatly enhanced, extending its applicability to new domains, including immunopeptidomics and MS3-based TMT quantification experiments. MS²PIP is freely available at https://iomics.ugent.be/ms2pip/., Arthur Declercq, Lennart Martens and Ralf Gabriels acknowledge funding from the Research Foundation Flanders (FWO) [12B7123N, G010023N, G028821N, 1SE3722]; Robbin Bouwmeester acknowledges funding from the Vlaams Agentschap Innoveren en Ondernemen [HBC.2020.2205]; Sven Degroeve and Lennart Martens acknowledge funding from the European Union's Horizon 2020 Programme (H2020-INFRAIA-2018-1) [823839]; Lennart Martens acknowledges funding from the Ghent University Concerted Research Action [BOF21/GOA/033]. Eduard Sabidó and Cristina Chiva acknowledge support from the Spanish Ministry of Science, Innovation and Universities (PID2020-115092GB-I00), “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208, and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). This work has been supported by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union. Funding for open access charge: the Research Foundation Flanders (FWO) [G028821N].
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Isotopologue multipoint calibration for proteomics biomarker quantification in clinical practice

  • Chiva, Cristina
  • Pastor, Olga
  • Trilla Fuertes, Lucía
  • Gámez Pozo, Angelo
  • Fresno Vara, Juan Ángel
  • Sabidó Aguadé, Eduard, 1981-
Targeted proteomics has become the method of choice for biomarker validation in human biopsies due to its high sensitivity, reproducibility, accuracy, and precision. However, for targeted proteomics to be transferred to clinical routine there is the need to reduce its complexity, make its procedures simpler, increase its throughput, and improve its analytical performance. Here we present the Isotopologue Multipoint Calibration (ImCal) quantification strategy, which uses a mix of isotopologue peptides to generate internal multipoint calibration curves for each individual sample and to accurately quantify biomarker peptides in clinical applications without the need of expert supervision. ImCal relies on the use of five different isotopically-labelled peptides of different nominal mass mixed at different concentrations to be used as an internal calibration curve for each endogenous peptide. The use of internal multipoint calibration curves is well-suited for the generation of ready-to-use biomarker kits for clinical applications as it is compatible with both high- and low-resolution mass spectrometers and different levels of endogenous peptide, it eliminates the need for blank matrixes required in external curves, it allows the evaluation of matrix effects and the valid quantification range in each individual sample, and it does not require expert adjustment. We used the ImCal method to quantify HER2 in 35 breast cancer formalin-fixed paraffin-embedded patient samples, revealing a high degree of heterogeneity among patients, which contrasts with the homogeneous immunohistochemistry patient classification. Our work illustrates how an improvement of mass spectrometry methods for biomarker quantification can provide fine-grain patient stratification, and thus better disease diagnostic and prognosis., The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by Grant PT17/0019/0021 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, “Centro de Excelencia Severo Ochoa 2013–2017”, Grant SEV-2012-0208, and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” Grant (2017SGR595). This project has also received funding from the European Union’s Horizon 2020 research and innovation program under Grant Agreement No. 823839 (EPIC-XS). L.T.-F. is supported by Spanish Economy and Competitiveness Ministry (Grant DI-15-07614). The Molecular Oncology and Pathology Lab is supported by Instituto de Salud Carlos III, Spanish Economy and Competitiveness Ministry, Spain, and cofunded by the FEDER program, “Una forma de hacer Europa” (Grant PI15/01310).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Deconwolf enables high-performance deconvolution of widefield fluorescence microscopy images

  • Wernersson, Erik
  • Gelali, Eleni
  • Girelli, Gabriele
  • Wang, Su
  • Castillo, David
  • Mattsson Langseth, Christoffer
  • Verron, Quentin
  • Nguyen, Huy Q.
  • Chattoraj, Shyamtanu
  • Martinez Casals, Anna
  • Blom, Hans
  • Lundberg, Emma
  • Nilsson, Mats
  • Martí Renom, Marc A.
  • Wu, Chao-Ting
  • Crosetto, Nicola
  • Bienko, Magda
Microscopy-based spatially resolved omic methods are transforming the life sciences. However, these methods rely on high numerical aperture objectives and cannot resolve crowded molecular targets, limiting the amount of extractable biological information. To overcome these limitations, here we develop Deconwolf, an open-source, user-friendly software for high-performance deconvolution of widefield fluorescence microscopy images, which efficiently runs on laptop computers. Deconwolf enables accurate quantification of crowded diffraction limited fluorescence dots in DNA and RNA fluorescence in situ hybridization images and allows robust detection of individual transcripts in tissue sections imaged with ×20 air objectives. Deconvolution of in situ spatial transcriptomics images with Deconwolf increased the number of transcripts identified more than threefold, while the application of Deconwolf to images obtained by fluorescence in situ sequencing of barcoded Oligopaint probes drastically improved chromosome tracing. Deconwolf greatly facilitates the use of deconvolution in many bioimaging applications., The authors acknowledge the Spatial Proteomics National Facility at SciLifeLab, funded by SciLifeLab and the Swedish Research Council (grant no. VR-RFI 2019-00217) as a member of the National Microscopy Infrastructure (NMI). The authors also acknowledge the Advanced Light Microscopy facility at KTH-SciLifeLab, also part of the National Microscopy Infrastructure NMI (grant no. VR-RFI 2019-00217), for support with STED and confocal imaging. The authors thank Atlas Antibodies for providing the tissue sample used to compare images acquired using a widefield and a confocal microscope. This work was supported by funding from the Swedish Cancer Research Foundation (Cancerfonden, grant no. CAN 2018/604) and the Swedish Research Council (grant no. 2019-01238) to M.N.; by funding from the Knut and Alice Wallenberg Foundation (grant no. KAW 2018.0172), the Erling Persson Foundation, and the European Union’s Horizon 2020 research and innovation programme (grant no. EPIC-XS_823839) to E.L.; by funding from the National Human Genome Research Institute of the National Institutes of Health (grant no. RM1HG011016) to C.-t.W. and M.A.M.-R.; by funding from the National Institutes of Health (grants no. RM1HG011016; R01HD091797; R01GM123289) and Bruker Nano Inc. to C.-t.W.; by funding from the Swedish Cancer Research Foundation (Cancerfonden, grant no. 21 1785 Pj), the Swedish Foundation for Strategic Research (SSF, grant no. BD15_0095), the Swedish Research Council (grant. no. 2022-00721), and the Strategic Research Programme in Cancer (StratCan, now Cancer Research KI) at Karolinska Institutet (grant. no. 2201) to N.C.; and by funding from the Ragnar Söderberg Foundation (Fellows in Medicine 2016), the Human Frontier Science Program (HFSP Career Development Award), the Swedish Cancer Research Foundation (Cancerfonden, grant no. 22 2240 Pj 01 H), the Swedish Research Council (grant. no. 2020-02657_3), and the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant no. StG-2016_GENOMIS_715727) to M.B.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Koina: Democratizing machine learning for proteomics research

  • Lautenbacher, Ludwig
  • Sabidó Aguadé, Eduard, 1981-
  • Wilhelm, Mathias
Recent developments in machine learning (ML) and deep learning have immense potential for applications in proteomics, such as generating spectral libraries, improving peptide identification, and optimizing targeted acquisition modes. Although new ML models are regularly published, the rate at which the community adopts these models is slow. This is in part due to a lack of findability and accessibility of these models as well as the technical challenges involved in incorporating these models into data analysis pipelines and demonstrating their reusability for end-users. Here we show Koina, an open-source decentralized and online-accessible model repository to facilitate publication of ML models. Koina enables ML model usage via an easy-to-use online interface, facilitating the integration of ML models in data analysis pipelines. Using the widely used FragPipe computational platform as an example, we demonstrate how Koina can be integrated with existing proteomics software tools and how these integrations improve data analysis., This research was in part funded by the Munich Data Science Institute (L.L.); European Union¿s Horizon 2020 Program under Grant Agreement 823839 [H2020-INFRAIA-2018-1; EPIC-XS] (W.G.); an ERC Starting Grant [101077037] (E.K., M.W., W.G.); National Institutes of Health grants R01-GM094231, 1U01CA288888, and U24-CA271037 (K.L.Y., F.Y., K.L., A.I.N.); R35-GM150723 (B.C.S.); R35-GM150583 and R00-HD090201 (D.B.W.); the University of Michigan Rackham Predoctoral Fellowship (K.L.Y.); the Research Foundation Flanders (FWO) [12B7123N, 12A6L24N, 1SH9O24N] (R.G., R.B., R.D.); National Science Foundation (NSF) Grant No. DBI-2011271 (H.T., Y.H.); the Spanish Ministry of Science and Innovation [PID2020-115092GB-I00] (E.S.); and NIH grants 5U24DK133658-02 (Mi.W., M.S).
Repisalud
Publicación Artículo científico (JournalArticle)

Proteomics of colorectal tumors identifies the role of CAVIN1 in tumor relapse.

  • Martinez-Val, Ana
  • Van der Hoeven, Leander
  • Bekker-Jensen, Dorte B
  • Jørgensen, Margarita Melnikova
  • Nors, Jesper
  • Franciosa, Giulia
  • Andersen, Claus L
  • Bramsen, Jesper B
  • Olsen, Jesper V
Colorectal cancer molecular signatures derived from omics data can be employed to stratify CRC patients and aid decisions about therapies or evaluate prognostic outcome. However, molecular biomarkers for identification of patients at increased risk of disease relapse are currently lacking. Here, we present a comprehensive multi-omics analysis of a Danish colorectal cancer tumor cohort composed of 412 biopsies from tumors of 371 patients diagnosed at TNM stage II or III. From mass spectrometry-based patient proteome profiles, we classified the tumors into four molecular subtypes, including a mesenchymal-like subtype. As the mesenchymal-rich tumors are known to represent the most invasive and metastatic phenotype, we focused on the protein signature defining this subtype to evaluate their potential as relapse risk markers. Among signature-specific proteins, we followed-up Caveolae-Associated Protein-1 (CAVIN1) and demonstrated its role in tumor progression in a 3D in vitro model of colorectal cancer. Compared to previous omics analyses of CRC, our multi-omics classification provided deeper insights into EMT in cancer cells with stronger correlations with risk of relapse.
Repisalud
Publicación Artículo científico (JournalArticle)

Goat Milk Exosomes As Natural Nanoparticles for Detecting Inflammatory Processes By Optical Imaging.

  • Santos-Coquillat, Ana
  • González, María Isabel
  • Clemente-Moragón, Agustín
  • González-Arjona, Mario
  • Albaladejo-García, Virginia
  • Peinado, Héctor
  • Muñoz, Javier
  • Ximénez Embún, Pilar
  • Ibañez, Borja
  • Oliver, Eduardo
  • Desco, Manuel
  • Salinas, Beatriz
Exosomes are cell-derived nanovesicles with a proven intercellular signaling role in inflammation processes and immune response. Due to their natural origin and liposome-like structure, these nanometer-scale vesicles have emerged as novel platforms for therapy and diagnosis. In this work, goat milk exosomes are isolated and fully characterized in terms of their physicochemical properties, proteomics, and biochemical profile in healthy mice, and used to detect inflammatory processes by optical imaging. For the in vitro and in vivo experiments, the exosomes are covalently labeled with the commercial fluorophores sulfo-Cyanine 5 and BODIPY-FL to create nanoprobes. In vitro studies using confocal imaging, flow cytometry, and colorimetric assays confirm the internalization of the nanoprobes as well their lack of cytotoxicity in macrophage populations RAW 264.7. Optical imaging in the mouse peritoneal region confirms the in vivo ability of one of the nanoprobes to localize inflammatory processes. In vivo imaging shows exosome uptake in the inflamed peritoneal region, and flow-cytometric analysis of peritonitis exudates confirms the uptake by macrophage and neutrophil populations. These results support the promising use of goat milk exosomes as natural probes in the detection of inflammatory processes.
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

beta-RA Targets Mitochondrial Metabolism and Adipogenesis, Leading to Therapeutic Benefits against CoQ Deficiency and Age-Related Overweight

  • Hidalgo Gutiérrez, Agustín|||0000-0001-6414-6859
  • Barriocanal Casado, Eliana|||0000-0001-8828-1182
  • Díaz Casado, María Elena|||0000-0003-1172-6475
  • González García, Pilar
  • Acuña Castroviejo, Darío|||0000-0002-9680-1560
  • López García, Luis Carlos|||0000-0003-3355-0298
This work was supported by grants from Ministerio de Ciencia e Innovacion, Spain, and the ERDF (grant number RTI2018-093503-B-100); from the Muscular Dystrophy Association (MDA602322); from the Junta de Andalucia (grant number P20_00134); from the University of Granada (grant reference "UNETE," UCE-PP2017-06); and by EPIC-XS, project number 823839, funded by the Horizon 2020 program of the European Union. P.G.-G. is a "FPU fellow" from the Ministerio de Universidades, Spain. M.E.D.-C. is supported by the Muscular Dystrophy Association. E.B.-C. is supported by the Junta de Andalucia. A.H.-G. was partially supported by the "FPU program" and the research program from the University of Granada., Primary mitochondrial diseases are caused by mutations in mitochondrial or nuclear genes, leading to the abnormal function of specific mitochondrial pathways. Mitochondrial dysfunction is also a secondary event in more common pathophysiological conditions, such as obesity and metabolic syndrome. In both cases, the improvement and management of mitochondrial homeostasis remain challenging. Here, we show that beta-resorcylic acid (beta-RA), which is a natural phenolic compound, competed in vivo with 4-hydroxybenzoic acid, which is the natural precursor of coenzyme Q biosynthesis. This led to a decrease in demethoxyubiquinone, which is an intermediate metabolite of CoQ biosynthesis that is abnormally accumulated in Coq9(R239X) mice. As a consequence, beta-RA rescued the phenotype of Coq9(R239X) mice, which is a model of primary mitochondrial encephalopathy. Moreover, we observed that long-term treatment with beta-RA also reduced the size and content of the white adipose tissue (WAT) that is normally accumulated during aging in wild-type mice, leading to the prevention of hepatic steatosis and an increase in survival at the elderly stage of life. The reduction in WAT content was due to a decrease in adipogenesis, an adaptation of the mitochondrial proteome in the kidneys, and stimulation of glycolysis and acetyl-CoA metabolism. Therefore, our results demonstrate that beta-RA acted through different cellular mechanisms, with effects on mitochondrial metabolism; as such, it may be used for the treatment of primary coenzyme Q deficiency, overweight, and hepatic steatosis., Spanish Government, European Commission RTI2018-093503-B-100, Muscular Dystrophy Association MDA602322, Junta de Andalucia P20_00134, University of Granada UCE-PP2017-06, EPIC-XS - Horizon 2020 program of the European Union 823839, Muscular Dystrophy Association, Junta de Andalucia, Spanish Government, University of Granada
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

The Q-junction and the inflammatory response are critical pathological and therapeutic factors in CoQ deficiency

  • González García, Pilar
  • Díaz Casado, María Elena|||0000-0003-1172-6475
  • Hidalgo Gutiérrez, Agustín|||0000-0001-6414-6859
  • Jiménez Sánchez, Laura
  • Bakkali, Mohammed|||0000-0002-9079-8452
  • Barriocanal Casado, Eliana|||0000-0001-8828-1182
  • Escames Rosa, Germaine|||0000-0003-1256-7656
  • López García, Luis Carlos|||0000-0003-3355-0298
Defects in Coenzyme Q (CoQ) metabolism have been associated with primary mitochondrial disorders, neurodegenerative diseases and metabolic conditions. The consequences of CoQ deficiency have not been fully addressed, and effective treatment remains challenging. Here, we use mice with primary CoQ deficiency (Coq9R239X), and we demonstrate that CoQ deficiency profoundly alters the Q-junction, leading to extensive changes in the mitochondrial proteome and metabolism in the kidneys and, to a lesser extent, in the brain. CoQ deficiency also induces reactive gliosis, which mediates a neuroinflammatory response, both of which lead to an encephalopathic phenotype. Importantly, treatment with either vanillic acid (VA) or β-resorcylic acid (β-RA), two analogs of the natural precursor for CoQ biosynthesis, partially restores CoQ metabolism, particularly in the kidneys, and induces profound normalization of the mitochondrial proteome and metabolism, ultimately leading to reductions in gliosis, neuroinflammation and spongiosis and, consequently, reversing the phenotype. Together, these results provide key mechanistic insights into defects in CoQ metabolism and identify potential disease biomarkers. Furthermore, our findings clearly indicate that the use of analogs of the CoQ biosynthetic precursor is a promising alternative therapy for primary CoQ deficiency and has potential for use in the treatment of more common neurodegenerative and metabolic diseases that are associated with secondary CoQ deficiency., MCIN/AEI, Spain, European Commission RTI2018093503-B-100, Muscular Dystrophy Association MDA-602322, Junta de Andalucia P20_00134 PEER-00832020, EPIC-XS - Horizon 2020 programme of the European Union 823839, "Plan Propio de Investigacion" from the University of Granada Junta de Andalucia
Digibug. Repositorio Institucional de la Universidad de Granada
Publicación Artículo científico (JournalArticle)

Phosphorylation of cytosolic hPGK1 affects protein stability and ligand binding: implications for its subcellular targeting in cancer

  • Pacheco García, Juan Luis
  • Cano Muñoz, Mario
  • Loginov, Dmitry S.
  • Vankova, Pavla
  • Man, Petr
  • Pey Rodríguez, Ángel Luis
This work was supported by the ERDF/Spanish Ministry of Science, Innovation and Universities – State Research Agency (Grant number RTI2018-096246-B-I00), Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (Grant number P18-RT-2413), ERDF/Counselling of Economic transformation, Industry, Knowledge and Universities (Grant B-BIO-84-UGR20). Access to the Structural Mass Spectrometry core facility – BioCeV was funded by the CIISB, Instruct-CZ Centre of Instruct-ERIC EU consortium, supported by MEYS CR (LM2023042). European Regional Development Fund-Project ‘UP CIISB’ (No. CZ.02.1.01/0.0/0.0/18_046/0015974) and EPIC-XS H2020 (823839) are gratefully acknowledged. Funding for open access charge: Universidad de Granada/CBUA. MC-M was supported by the Spanish Ministry of Economy and Competitiveness. MC-M was supported by a Post-doctoral Research Program, Juan de la Cierva (JDC2022-049681-I)., Human phosphoglycerate kinase 1(hPGK1) is a key glycolytic enzyme that regulates the balance between ADP and ATP concentrations inside the cell. Phosphorylation of hPGK1 at S203 and S256 has been associated with enzyme import from the cytosol to the mitochondria and the nucleus respectively. These changes in subcellular locations drive tumorigenesis and are likely associated with site-specific changes in protein stability. In this work, we investigate the effects of site-specific phosphorylation on thermal and kinetic stability and protein structural dynamics by hydrogen-deuterium exchange (HDX) and molecular dynamics (MD) simulations. We also investigate the binding of 3-phosphoglycerate and Mg-ADP using these approaches. We show that the phosphomimetic mutation S256D reduces hPGK1 kinetic stability by 50-fold, with no effect of the mutation S203D. Calorimetric studies of ligand binding show a large decrease in affinity for Mg-ADP in the S256D variant, whereas Mg-ADP binding to the WT and S203D can be accurately investigated using protein kinetic stability and binding thermodynamic models. HDX and MD simulations confirmed the destabilization caused by the mutation S256D (with some long-range effects on stability) and its reduced affinity for Mg-ADP due to the strong destabilization of its binding site (particularly in the apo-state). Our research provides evidence suggesting that modifications in protein stability could potentially enhance the translocation of hPGK1 to the nucleus in cancer. While the structural and energetic basis of its mitochondrial import remain unknown., Grupo FQM-171, Departamento de Química Física, ERDF/Spanish Ministry of Science, Innovation and Universities – State Research Agency (RTI2018-096246-B-I00), Junta de Andalucía (P18-RT-2413), ERDF/Counselling of Economic transformation, Industry, Knowledge and Universities (B-BIO-84-UGR20), CIISB, MEYS CR (LM2023042), European Regional Development Fund-Project ‘UP CIISB’ (No. CZ.02.1.01/0.0/0.0/18_046/0015974), EPIC-XS H2020 (823839), Universidad de Granada/CBUA, Spanish Ministry of Economy and Competitiveness, Post-doctoral Research Program, Juan de la Cierva (JDC2022-049681-I)
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Unraveling the differential mechanisms of revascularization promoted by MSCs & ECFCs from adipose tissue or umbilical cord in a murine model of critical limb-threatening ischemia

  • Rojas Torres, Marta
  • Beltrán Camacho, Lucía
  • Martínez Val, Ana
  • Sánchez Gomar, Ismael
  • Eslava Alcón, Sara
  • Rosal Vela, Antonio
  • Jiménez Palomares, Margarita
  • Doiz Artázcoz, Esther
  • Martínez-Torija, Mario
  • Moreno-Luna, Rafael
  • Olsen, Jesper V.
  • Durán Ruiz, María del Carmen
Abstract Background Critical limb-threatening ischemia (CLTI) constitutes the most severe manifestation of peripheral artery disease, usually induced by atherosclerosis. CLTI patients suffer from high risk of amputation of the lower extremities and elevated mortality rates, while they have low options for surgical revascularization due to associated comorbidities. Alternatively, cell-based therapeutic strategies represent an effective and safe approach to promote revascularization. However, the variability seen in several factors such as cell combinations or doses applied, have limited their success in clinical trials, being necessary to reach a consensus regarding the optimal “cellular-cocktail” prior further application into the clinic. To achieve so, it is essential to understand the mechanisms by which these cells exert their regenerative properties. Herein, we have evaluated, for the first time, the regenerative and vasculogenic potential of a combination of endothelial colony forming cells (ECFCs) and mesenchymal stem cells (MSCs) isolated from adipose-tissue (AT), compared with ECFCs from umbilical cord blood (CB-ECFCs) and AT-MSCs, in a murine model of CLTI. Methods Balb-c nude mice (n:32) were distributed in four different groups (n:8/group): control shams, and ischemic mice (after femoral ligation) that received 50 μl of physiological serum alone or a cellular combination of ATMSCs with either CB-ECFCs or AT-ECFCs. Follow-up of blood flow reperfusion and ischemic symptoms was carried out for 21 days, when mice were sacrificed to evaluate vascular density formation. Moreover, the long-term molecular changes in response to CLTI and both cell combinations were analyzed in a proteomic quantitative approach. Results AT-MSCs with either AT- or CB-ECFCs, promoted a significant recovery of blood flow in CLTI mice 21 days post-ischemia. Besides, they modulated the inflammatory and necrotic related processes, although the CB group
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An Integrative Structural Biology Analysis of Von Willebrand Factor Binding and Processing by ADAMTS-13 in Solution

  • Amo-Maestro, Laura del
  • Sagar, Amin
  • Pompach, Petr
  • Goulas, Theodoros
  • Scavenius, Carsten
  • Ferrero, Diego
  • Castrillo-Briceño, Mariana
  • Taulés, Marta
  • Enghild, Jan J.
  • Bernadó, Pau
  • Gomis-Rüth, F. Xavier
Von Willebrand Factor (vWF), a 300-kDa plasma protein key to homeostasis, is cleaved at a single site by multi-domain metallopeptidase ADAMTS-13. vWF is the only known substrate of this peptidase, which circulates in a latent form and becomes allosterically activated by substrate binding. Herein, we characterised the complex formed by a competent peptidase construct (AD13-MDTCS) comprising metallopeptidase (M), disintegrin-like (D), thrombospondin (T), cysteine-rich (C), and spacer (S) domains, with a 73-residue functionally relevant vWF-peptide, using nine complementary techniques. Pull-down assays, gel electrophoresis, and surface plasmon resonance revealed tight binding with sub-micromolar affinity. Cross-linking mass spectrometry with four reagents showed that, within the peptidase, domain D approaches M, C, and S. S is positioned close to M and C, and the peptide contacts all domains. Hydrogen/deuterium exchange mass spectrometry revealed strong and weak protection for C/D and M/S, respectively. Structural analysis by multi-angle laser light scattering and small-angle X-ray scattering in solution revealed that the enzyme adopted highly flexible unbound, latent structures and peptide-bound, active structures that differed from the AD13-MDTCS crystal structure. Moreover, the peptide behaved like a self-avoiding random chain. We integrated the results with computational approaches, derived an ensemble of structures that collectively satisfied all experimental restraints, and discussed the functional implications. The interaction conforms to a ‘fuzzy complex’ that follows a ‘dynamic zipper’ mechanism involving numerous reversible, weak but additive interactions that result in strong binding and cleavage. Our findings contribute to illuminating the biochemistry of the vWF:ADAMTS-13 axis., This study was supported in part by grants from Spanish, French, Danish and Catalan public and private bodies (grant/fellowship references PID2019-107725RG-I00, BES-2015-074583, ANR-10-LABX-12-01, 6108-00031B, 8022-00385B, LF18039, NNF18OC0032724, Novo Nordisk Foundation “Bio-MS”, 2017SGR3 and Fundació “La Marató de TV3” 201815). This work was also supported by EPICS-XS, project 823839, funded by the Horizon 2020 programme of the European Union. The CBS is a member of France-BioImaging (FBI) and the French Infrastructure for Integrated Structural Biology (FRISBI), which are national infrastructures supported by the French National Research Agency (grants ANR-10-INBS-04-01 and ANR-10-INBS-05, respectively). Finally, we acknowledge the Structural Mass Spectrometry Unit of CIISB, an Instruct-CZ Centre, which was supported by MEYS CR (LM2018127).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PDBe-KB: collaboratively defining the biological context of structural data

  • PDBe-KB consortium
  • Varadi, Mihaly
  • Anyango, Stephen
  • Armstrong, David
  • Berrisford, John
  • Choudhary, Preeti
  • Deshpande, Mandar
  • Nadzirin, Nurul
  • Nair, Sreenath S.
  • Pravda, Lukáš
  • Tanweer, Ahsan
  • Al-Lazikani, Bissan
  • Andreini, Claudia
  • Barton, Geoffrey J.
  • Bednar, David
  • Berka, Karel
  • Blundell, Tom
  • Brock, Kelly P.
  • Carazo, José M.
  • Damborsky, Jiri
  • David, Alessia
  • Dey, Sucharita
  • Dunbrack, Roland
  • Fernández-Recio, Juan
  • Fraternali, Franca
  • Gibson, Toby
  • Helmer-Citterich, Manuela
  • Hoksza, David
  • Hopf, Thomas
  • Jakubec, David
  • Kannan, Natarajan
  • Krivak, Radoslav
  • Kumar, Manjeet
  • Levy, Emmanuel D.
  • London, Nir
  • Macías, José Ramón
  • Srivatsan, Madhusudhan M.
  • Marks, Debora S.
  • Martens, Lennart
  • McGowan, Stuart A.
  • McGreig, Jake E.
  • Modi, Vivek
  • Parra, R. Gonzalo
  • Pepe, Gerardo
  • Piovesan, Damiano
  • Prilusky, Jaime
  • Putignano, Valeria
  • Radusky, Leandro G.
  • Ramasamy, Pathmanaban
  • Rausch, Atilio O.
  • Reuter, Nathalie
  • Rodríguez-Lumbreras, Luis A.
  • Rollins, Nathan J.
  • Rosato, Antonio
  • Rubach, Paweł
  • Serrano, Luis
  • Singh, Gulzar
  • Skoda, Petr
  • Sorzano, Carlos Óscar S.
  • Stourac, Jan
  • Sulkowska, Joanna I.
  • Svobodova, Radka
  • Tichshenko, Natalia
  • Tosatto, Silvio C. E.
  • Vranken, Wim
  • Wass, Mark N.
  • Xue, Dandan
  • Thornton, Janet
  • Sternberg, Michael
  • Orengo, Christine A.
  • Velankar, Sameer
The Protein Data Bank in Europe – Knowledge Base (PDBe-KB, https://pdbe-kb.org) is an open collaboration between world-leading specialist data resources contributing functional and biophysical annotations derived from or relevant to the Protein Data Bank (PDB). The goal of PDBe-KB is to place macromolecular structure data in their biological context by developing standardised data exchange formats and integrating functional annotations from the contributing partner resources into a knowledge graph that can provide valuable biological insights. Since we described PDBe-KB in 2019, there have been significant improvements in the variety of available annotation data sets and user functionality. Here, we provide an overview of the consortium, highlighting the addition of annotations such as predicted covalent binders, phosphorylation sites, effects of mutations on the protein structure and energetic local frustration. In addition, we describe a library of reusable web-based visualisation components and introduce new features such as a bulk download data service and a novel superposition service that generates clusters of superposed protein chains weekly for the whole PDB archive., ELIXIR [IDP implementation study]; Biotechnology and Biological Sciences Research Council via the 3D-Gateway [BB/T01959X/1]; FunPDBe [BB/P024351/1]; European Molecular Biology Laboratory-European Bioinformatics Institute who supported this work; J.D. acknowledges support from the Ministry of Education, Youth and Sport of the Czech Republic [INBIO CZ.02.1.01/0.0/0.0/16_026/0008451]; R.S., K.B. and J.D. also acknowledge support from the Ministry of Education, Youth and Sport of the Czech Republic [ELIXIR-CZ LM2018131]; L.M. acknowledges support from the European Union's Horizon 2020 Programme (H2020-INFRAIA-2018-1) [823839]; Research Foundation Flanders (FWO) [G032816N, G042518N, G028821N]; W.V. acknowledges support from the Research Foundation Flanders (FWO) [G032816N, G028821N]; A.R. acknowledges support from the Fondazione Cassa Di Risparmio di Firenze [24316]; European Commission [101017567]; M.H.C. acknowledges the AIRC project to MHC [IG 23539]; J.F.-R. acknowledges support from the Spanish Ministry of Science and Innovation [PID2019-110167RB-I00]; N.R. acknowledges support from the Norwegian Research Council (Norges Forskningsråd) [288008]; E.D.L. acknowledges support from the European Union's Horizon 2020 research and innovation programme [819318]; M.J.E.S. acknowledges support from the Wellcome Trust [104955/Z/14/Z, 218242/Z/19/Z]. Funding for open access charge: Biotechnology and Biological Sciences Research Council grant [BB/T01959X/1]; Wellcome Trust [104955/Z/14/Z and 218242/Z/19/Z].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Selective ribosome profiling reveals a role for SecB in the co-translational inner membrane protein biogenesis

  • Eismann, Lena
  • Fijalkowski, Igor
  • Galmozzi, Carla V.
  • Koubek, Jiří
  • Tippmann, Frank
  • Van Damme, Petra
  • Kramer, Günter
The chaperone SecB has been implicated in de novo protein folding and translocation across the membrane, but it remains unclear which nascent polypeptides SecB binds, when during translation SecB acts, how SecB function is coordinated with other chaperones and targeting factors, and how polypeptide engagement contributes to protein biogenesis. Using selective ribosome profiling, we show that SecB binds many nascent cytoplasmic and translocated proteins generally late during translation and controlled by the chaperone trigger factor. Revealing an uncharted role in co-translational translocation, inner membrane proteins (IMPs) are the most prominent nascent SecB interactors. Unlike other substrates, IMPs are bound early during translation, following the membrane targeting by the signal recognition particle. SecB remains bound until translation is terminated, and contributes to membrane insertion. Our study establishes a role of SecB in the co-translational maturation of proteins from all cellular compartments and functionally implicates cytosolic chaperones in membrane protein biogenesis., The work was supported by the Deutsche Forschungsgemeinschaft (DFG KR 3593/2-1). I.F. was supported by FWO travel grant (#V439517N) and FWO junior postdoctoral fellowship (#12I5517N). J.K. was supported by the European Research Council (Horizon 2020 Individual Fellowship, CoCoAssembly 895164). P.V.D. was supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (PROPHECY grant agreement no. 803972) and by the Research Foundation Flanders (FWO-Vlaanderen), project number G051120N. This work has been supported by EPIC-XS, project number 823839, funded by the Horizon 2020 program of the European Union (TransFold 743118)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peroxiredoxin 2 is required for the redox mediated adaptation to exercise

  • Xia, Qin
  • Casas-Martínez, José C.
  • Zarzuela, Eduardo
  • Muñoz, Javier
  • Miranda-Vizuete, Antonio
  • Goljanek-Whysall, Katarzyna
  • McDonagh, Brian
© 2023 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., Exercise generates a site-specific increase in Reactive Oxygen Species (ROS) within muscle that promotes changes in gene transcription and mitochondrial biogenesis, required for the beneficial adaptive response. We demonstrate that Peroxiredoxin 2 (Prdx2), an abundant cytoplasmic 2-Cys peroxiredoxin, is required for the adaptive hormesis response to physiological levels of H2O2 in myoblasts and following exercise in C. elegans. A short bolus addition of H2O2 increases mitochondrial capacity and improves myogenesis of cultured myoblasts, this beneficial adaptive response was suppressed in myoblasts with decreased expression of cytoplasmic Prdxs. Moreover, a swimming exercise protocol in C. elegans increased mitochondrial content, fitness, survival and longevity in wild type (N2) worms. In contrast, prdx-2 mutant worms had decreased fitness, disrupted mitochondria, reduced survival and lifespan following exercise. Global proteomics following exercise identified distinct changes in the proteome of N2 and prdx-2 mutants. Furthermore, a redox proteomic approach to quantify reversible oxidation of specific Cysteine residues revealed a more reduced redox state in the non-exercised prdx-2 mutant strain that become oxidized following exercise. In contrast, specific Cys residues from regulatory proteins become more reduced in the N2 strain following exercise, establishing the key regulatory role of PRDX-2 in a redox signalling cascade following endogenous ROS generation. Our results demonstrate that conserved cytoplasmic 2-Cys Peroxiredoxins are required for the beneficial adaptive response to a physiological redox stress., QX studentship is funded by the Chinese Scholarship Council (CSC) 202006370047, JCCM studentship is funded by the College of Nursing Medicine and Health Sciences, University of Galway. The mass spectrometry work was funded by European Proteomics Infrastructure Consortium providing access (EPIC‐XS): Project number 823839., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Insights into the pathogenesis of primary hyperoxaluria type I from the structural dynamics of alanine:glyoxylate aminotransferase variants

  • Vankova, Pavla
  • Pacheco-García, Juan Luis
  • Loginov, Dmitry S.
  • Gómez-Mulas, Atanasio
  • Kádek, Alan
  • Martín-García, José M.
  • Salido, Eduardo
  • Man, Petr
  • Pey, Angel L.
15 pags., 6 figs., Primary hyperoxaluria type I (PH1) is caused by deficient alanine:glyoxylate aminotransferase (AGT) activity. PH1-causing mutations in AGT lead to protein mistargeting and aggregation. Here, we use hydrogen-deuterium exchange (HDX) to characterize the wild-type (WT), the LM (a polymorphism frequent in PH1 patients) and the LM G170R (the most common mutation in PH1) variants of AGT. We provide the first experimental analysis of AGT structural dynamics, showing that stability is heterogeneous in the native state and providing a blueprint for frustrated regions with potentially functional relevance. The LM and LM G170R variants only show local destabilization. Enzymatic transamination of the pyridoxal 5-phosphate cofactor bound to AGT hardly affects stability. Our study, thus, supports that AGT misfolding is not caused by dramatic effects on structural dynamics., Access to the Structural Mass Spectrometry core facility—BioCeV was funded by the CIISB, Instruct-CZCentre, supported by MEYS CR (LM2023042). Euro-pean Regional Development Fund-Project “UPCIISB” (No. CZ.02.1.01/0.0/0.0/18_046/0015974) andEPIC-XS H2020 (823839) are gratefully acknowledged.The research of JLP-G, AG-M, and ALP was sup-ported by the ERDF/Spanish Ministry of Science,Innovation and Universities—State Research Agency(Grant RTI2018-096246-B-I00), Consejerıa de Economıa, Conocimiento, Empresas y Universidad, Junta deAndalucıa (Grant P18-RT-2413) and ERDF/Counsel-ing of Economic transformation, Industry, Knowledgeand Universities (Grant B-BIO-84-UGR20, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RNF212B E3 ligase is essential for crossover designation and maturation during male and female meiosis in the mouse

  • Condezo, Yazmine B.
  • Sainz-Urruela, Raquel
  • Gomez-H, Laura
  • Salas-Lloret, Daniel
  • Felipe-Medina, Natalia
  • Bradley, Rachel
  • Wolff, Ian D.
  • Tanis, Stephanie
  • Barbero, José Luis
  • Sánchez-Martín, Manuel
  • Rooij, Dirk G. de
  • Hendriks, Ivo A.
  • Nielsen, Michael L.
  • González-Prieto, Román
  • Cohen, Paula E.
  • Pendás, Alberto M.
  • Llano, Elena
Meiosis, a reductional cell division, relies on precise initiation, maturation, and resolution of crossovers (COs) during prophase I to ensure the accurate segregation of homologous chromosomes during metaphase I. This process is regulated by the interplay of RING-E3 ligases such as RNF212 and HEI10 in mammals. In this study, we functionally characterized a recently identified RING-E3 ligase, RNF212B. RNF212B colocalizes and interacts with RNF212, forming foci along chromosomes from zygonema onward in a synapsis-dependent and DSB-independent manner. These consolidate into larger foci at maturing COs, colocalizing with HEI10, CNTD1, and MLH1 by late pachynema. Genetically, RNF212B foci formation depends on Rnf212 but not on Msh4, Hei10, and Cntd1, while the unloading of RNF212B at the end of pachynema is dependent on Hei10 and Cntd1. Mice lacking RNF212B, or expressing an inactive RNF212B protein, exhibit modest synapsis defects, a reduction in the localization of pro-CO factors (MSH4, TEX11, RPA, MZIP2) and absence of late CO-intermediates (MLH1). This loss of most COs by diakinesis results in mostly univalent chromosomes. Double mutants for Rnf212b and Rnf212 exhibit an identical phenotype to that of Rnf212b single mutants, while double heterozygous demonstrate a dosage-dependent reduction in CO number, indicating a functional interplay between paralogs. SUMOylome analysis of testes from Rnf212b mutants and pull-down analysis of Sumo- and Ubiquitin-tagged HeLa cells, suggest that RNF212B is an E3-ligase with Ubiquitin activity, serving as a crucial factor for CO maturation. Thus, RNF212 and RNF212B play vital, yet overlapping roles, in ensuring CO homeostasis through their distinct E3 ligase activities., This research was funded by the Ministerio de Ciencia e Innovación (PID2020–120326RB-I00 and PID2023-152857NB-I00) and Junta de Castilla y León (Unidad de Investigación Consolidada 066, CSI148P20 and CSI017P23) and R.G.-P. is funded by Dutch Cancer society, KWF Kankerbestrijding, Young Investigator Grant (11367/2017-2), and by Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía, Programa EMERGIA (EMERGIA20_00276). P.E.C., I.D.W., and R.B. are supported by funding from the Eunice Kennedy Shriver National Institute of Child Health and Development (HD041012 to P.E.C., HD106630 to I.D.W.). R.B. is supported by a graduate fellowship from The Natural Sciences and Engineering Research Council of Canada (PGSD-577969). R.S.-U. and Y.B.C. are funded by Ministerio de Ciencia (FPU) and L.G.-H. is funded by Max planck and JCyL (beginning of the project). M.L.N. lab was supported by the Novo Nordisk Foundation (NNF14CC0001). The proteomics technology applied was part of a project that has received funding from the European Union’s Horizon 2020 research and innovation program (EPIC-XS-823839). We are indebted to Attila Toth (Universitat Dresden, Germany), Neil Hunter (UC Davis, California, USA), Chao Yu (University of Gothenburg, Sweden), Christer Hoog (Karolinska Inst., Sweden), and Jeremy Wang (University of Pennsylvania) for providing Abs against CNTD1, RNF212, MZIP2, SYCE1, and TEX11 respectively. We thank J.M. Pereda (Centro de Investigación del Cáncer, Spain) for structural Zn-ring domain 3D modelling., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Pujana-Vaquerizo, Mikel
  • Martínez-Laosa, Belén
  • Ponce-Rodríguez, María
  • García-Longarte, Saioa
  • Mendizabal, Isabel
  • Gimeno, Ana
  • Rogalska, Malgorzata
  • Tan, Joycelyn
  • Cabrera, Diana
  • van Liempd, Sebastiaan
  • Ximenez-Embun, Pilar
  • Espinosa, Sergio
  • Fagoaga-Eugui, Maider
  • Peccati, Francesca
  • Zakrzewski, Maciej
  • Astobiza, Ianire
  • Arana-Castañares, Mikel
  • Cherkaoui, Sarah
  • Sendino, Maria
  • Martín-Barros, Inés
  • Ercilla, Amaia
  • Bozal-Basterra, Laura
  • Carlevaris, Onintza
  • Arruabarrena-Aristorena, Amaia
  • Pérez-Andrés, Encarnación
  • Santamaria-Zamorano, Telmo
  • Ferrer-Bonsoms, Juan A.
  • Carazo, Fernando
  • Ciesla, Maciej
  • Lobato, Cesar
  • Seoane, Joan
  • Martín-Martín, Natalia
  • Barrio, Rosa
  • Sutherland, James D.
  • Aransay, Ana M.
  • Falcón-Pérez, Juan Manuel
  • Martínez-Pastor, Barbara
  • Rubio, Angel
  • Blanco, Francisco J.
  • Hogarty, Michael D.
  • Morscher, Raphael J.
  • Berra, Edurne
  • Serwa, Remigiusz A.
  • Jiménez-Barbero, Jesús
  • Jiménez-Osés, Gonzalo
  • Efeyan, Alejo
  • Finley, Lydia
  • Lizcano, Jose M.
  • Muñoz, Javier
  • Valcarcel, Juan
  • Carracedo, Arkaitz
40 páginas, figuras y material suplementario., Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Machine learning integrated clinical-proteomics data identifies a 6-protein panel signature for atherosclerotic severity and enhanced patient stratification

  • Extremera-García, Mª Jesús
  • Rojas-Torres, Marta
  • Priego-Torres, Blanca
  • Beltrán-Camacho, Lucía
  • Eslava-Alcón, Sara
  • Rodríguez-Martín, Francisco
  • Benítez-Camacho, Josefa
  • Ballesteros-Ribelles, Antonio
  • Del Val, Ana Martínez
  • Olsen, Jesper
  • Lozano-Loaiza, Eva
  • González-García, Mª Ángela
  • Sanchez-Morillo, Daniel
  • Fernández-Vega, Alejandro
  • Montaner, Joan
  • Doiz, Esther
  • Rodriguez-Piñero, Manuel
  • Durán-Ruiz, Mª Carmen
[Data Availability] The data underlying this article are available within the article and its online supplementary material. Additional information will be provided by the corresponding authors upon reasonable request. In addition, mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository [100] with the data set identifier PXD049351., Atherosclerosis, a major cause of adverse cardiovascular events and mortality rates worldwide, stems from sustained lipid accumulation and subsequent chronic inflammation within the arterial walls. An early identification of patients at risk is crucial to prevent life-threatening thrombotic events and provide effective and personalized treatments. Leveraging the power of machine learning (ML) to enhance diagnostics and biomarker discovery, we applied a high-throughput approach using five ML classification algorithms (MLCA), integrating clinical and serum proteomic data from patients with carotid atherosclerotic stenosis (AT, n:60), dyslipidemic patients (DLP, n:55), and healthy controls (HC, n:66). As a result, a robust 6-protein panel (B2M, GPV, MMP9, PLF4, TSP1, and FB isoforms) was identified with a ROC-AUC value > 0.9 for all algorithms applied, highly discriminating AT patients compared to DLP or CTRL. The levels of these proteins were further validated in an independent external cohort, including patients presenting with acute atherothrombotic stroke, corroborating the potential of this panel as biomarker for atherosclerosis severity. In addition, the combined clinical-proteomic ML approach provided a more accurate patient stratification than the clinical or proteomic analysis alone. Mechanistically, the identified biomarkers highlight the importance of platelet activation, uncontrolled angiogenesis and intraplaque haemorrhage in the atherosclerotic process, underscoring the need for multipathway therapies to prevent unwanted thrombotic events., Funding for open access publishing: Universidad de Cádiz/CBUA This study was supported by the Institute of Health Carlos III, ISCIII (PI16-00784, PI20-00716, PI24-01161), all co-funded by European Regional Development Fund “A way to make Europe”. Mass spectrometry analysis was performed at the Novo Nordisk Foundation Center for Protein Research (CPR), which is partly funded by a donation from the Novo Nordisk Foundation (NNF14CC0001). Also, part of this work was funded with the EPIC-XS project no. 823839, funded by the European Union Horizon 2020 programme. Funding for open access publishing: Universidad de Cádiz/CBUA., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Koina: Democratizing machine learning for proteomics research

  • Lautenbacher, Ludwig
  • Sabidó Aguadé, Eduard, 1981-
  • Wilhelm, Mathias
Recent developments in machine learning (ML) and deep learning have immense potential for applications in proteomics, such as generating spectral libraries, improving peptide identification, and optimizing targeted acquisition modes. Although new ML models are regularly published, the rate at which the community adopts these models is slow. This is in part due to a lack of findability and accessibility of these models as well as the technical challenges involved in incorporating these models into data analysis pipelines and demonstrating their reusability for end-users. Here we show Koina, an open-source decentralized and online-accessible model repository to facilitate publication of ML models. Koina enables ML model usage via an easy-to-use online interface, facilitating the integration of ML models in data analysis pipelines. Using the widely used FragPipe computational platform as an example, we demonstrate how Koina can be integrated with existing proteomics software tools and how these integrations improve data analysis., This research was in part funded by the Munich Data Science Institute (L.L.); European Union¿s Horizon 2020 Program under Grant Agreement 823839 [H2020-INFRAIA-2018-1; EPIC-XS] (W.G.); an ERC Starting Grant [101077037] (E.K., M.W., W.G.); National Institutes of Health grants R01-GM094231, 1U01CA288888, and U24-CA271037 (K.L.Y., F.Y., K.L., A.I.N.); R35-GM150723 (B.C.S.); R35-GM150583 and R00-HD090201 (D.B.W.); the University of Michigan Rackham Predoctoral Fellowship (K.L.Y.); the Research Foundation Flanders (FWO) [12B7123N, 12A6L24N, 1SH9O24N] (R.G., R.B., R.D.); National Science Foundation (NSF) Grant No. DBI-2011271 (H.T., Y.H.); the Spanish Ministry of Science and Innovation [PID2020-115092GB-I00] (E.S.); and NIH grants 5U24DK133658-02 (Mi.W., M.S).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Updated MS²PIP web server supports cutting-edge proteomics applications

  • Declercq, Arthur
  • Bouwmeester, Robbin
  • Chiva, Cristina
  • Sabidó Aguadé, Eduard, 1981-
  • Hirschler, Aurélie
  • Carapito, Christine
  • Martens, Lennart
  • Degroeve, Sven
  • Gabriels, Ralf
Interest in the use of machine learning for peptide fragmentation spectrum prediction has been strongly on the rise over the past years, especially for applications in challenging proteomics identification workflows such as immunopeptidomics and the full-proteome identification of data independent acquisition spectra. Since its inception, the MS²PIP peptide spectrum predictor has been widely used for various downstream applications, mostly thanks to its accuracy, ease-of-use, and broad applicability. We here present a thoroughly updated version of the MS²PIP web server, which includes new and more performant prediction models for both tryptic- and non-tryptic peptides, for immunopeptides, and for CID-fragmented TMT-labeled peptides. Additionally, we have also added new functionality to greatly facilitate the generation of proteome-wide predicted spectral libraries, requiring only a FASTA protein file as input. These libraries also include retention time predictions from DeepLC. Moreover, we now provide pre-built and ready-to-download spectral libraries for various model organisms in multiple DIA-compatible spectral library formats. Besides upgrading the back-end models, the user experience on the MS²PIP web server is thus also greatly enhanced, extending its applicability to new domains, including immunopeptidomics and MS3-based TMT quantification experiments. MS²PIP is freely available at https://iomics.ugent.be/ms2pip/., Arthur Declercq, Lennart Martens and Ralf Gabriels acknowledge funding from the Research Foundation Flanders (FWO) [12B7123N, G010023N, G028821N, 1SE3722]; Robbin Bouwmeester acknowledges funding from the Vlaams Agentschap Innoveren en Ondernemen [HBC.2020.2205]; Sven Degroeve and Lennart Martens acknowledge funding from the European Union's Horizon 2020 Programme (H2020-INFRAIA-2018-1) [823839]; Lennart Martens acknowledges funding from the Ghent University Concerted Research Action [BOF21/GOA/033]. Eduard Sabidó and Cristina Chiva acknowledge support from the Spanish Ministry of Science, Innovation and Universities (PID2020-115092GB-I00), “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208, and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). This work has been supported by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union. Funding for open access charge: the Research Foundation Flanders (FWO) [G028821N].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Deconwolf enables high-performance deconvolution of widefield fluorescence microscopy images

  • Wernersson, Erik
  • Gelali, Eleni
  • Girelli, Gabriele
  • Wang, Su
  • Castillo, David
  • Mattsson Langseth, Christoffer
  • Verron, Quentin
  • Nguyen, Huy Q.
  • Chattoraj, Shyamtanu
  • Martinez Casals, Anna
  • Blom, Hans
  • Lundberg, Emma
  • Nilsson, Mats
  • Martí Renom, Marc A.
  • Wu, Chao-Ting
  • Crosetto, Nicola
  • Bienko, Magda
Microscopy-based spatially resolved omic methods are transforming the life sciences. However, these methods rely on high numerical aperture objectives and cannot resolve crowded molecular targets, limiting the amount of extractable biological information. To overcome these limitations, here we develop Deconwolf, an open-source, user-friendly software for high-performance deconvolution of widefield fluorescence microscopy images, which efficiently runs on laptop computers. Deconwolf enables accurate quantification of crowded diffraction limited fluorescence dots in DNA and RNA fluorescence in situ hybridization images and allows robust detection of individual transcripts in tissue sections imaged with ×20 air objectives. Deconvolution of in situ spatial transcriptomics images with Deconwolf increased the number of transcripts identified more than threefold, while the application of Deconwolf to images obtained by fluorescence in situ sequencing of barcoded Oligopaint probes drastically improved chromosome tracing. Deconwolf greatly facilitates the use of deconvolution in many bioimaging applications., The authors acknowledge the Spatial Proteomics National Facility at SciLifeLab, funded by SciLifeLab and the Swedish Research Council (grant no. VR-RFI 2019-00217) as a member of the National Microscopy Infrastructure (NMI). The authors also acknowledge the Advanced Light Microscopy facility at KTH-SciLifeLab, also part of the National Microscopy Infrastructure NMI (grant no. VR-RFI 2019-00217), for support with STED and confocal imaging. The authors thank Atlas Antibodies for providing the tissue sample used to compare images acquired using a widefield and a confocal microscope. This work was supported by funding from the Swedish Cancer Research Foundation (Cancerfonden, grant no. CAN 2018/604) and the Swedish Research Council (grant no. 2019-01238) to M.N.; by funding from the Knut and Alice Wallenberg Foundation (grant no. KAW 2018.0172), the Erling Persson Foundation, and the European Union’s Horizon 2020 research and innovation programme (grant no. EPIC-XS_823839) to E.L.; by funding from the National Human Genome Research Institute of the National Institutes of Health (grant no. RM1HG011016) to C.-t.W. and M.A.M.-R.; by funding from the National Institutes of Health (grants no. RM1HG011016; R01HD091797; R01GM123289) and Bruker Nano Inc. to C.-t.W.; by funding from the Swedish Cancer Research Foundation (Cancerfonden, grant no. 21 1785 Pj), the Swedish Foundation for Strategic Research (SSF, grant no. BD15_0095), the Swedish Research Council (grant. no. 2022-00721), and the Strategic Research Programme in Cancer (StratCan, now Cancer Research KI) at Karolinska Institutet (grant. no. 2201) to N.C.; and by funding from the Ragnar Söderberg Foundation (Fellows in Medicine 2016), the Human Frontier Science Program (HFSP Career Development Award), the Swedish Cancer Research Foundation (Cancerfonden, grant no. 22 2240 Pj 01 H), the Swedish Research Council (grant. no. 2020-02657_3), and the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant no. StG-2016_GENOMIS_715727) to M.B.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Quality standards in proteomics research facilities: Common standards and quality procedures are essential for proteomics facilities and their users

  • Chiva, Cristina
  • Mendes Maja, Teresa
  • Panse, Christian
  • Stejskal, Karel
  • Douché, Thibaut
  • Matondo, Mariette
  • Loew, Damarys
  • Helm, Dominic
  • Rettel, Mandy
  • Mechtler, Karl
  • Impens, Francis
  • Nanni, Paolo
  • Shevchenko, Anna
  • Sabidó Aguadé, Eduard, 1981-
Proteomics research infrastructures and core facilities within the Core for Life alliance advocate for community policies for quality control to ensure high standards in proteomics services., The CRG/UPF Proteomics Unit is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D+i 2013‐2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, “Centro de Excelencia Severo Ochoa 2013‐2017”, SEV‐2012‐ 0208, and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). The VIB Proteomics Core acknowledges support from the VIB Tech Watch Fund and FWO‐SBO Project S006617N. Research in the Mechtler lab was supported by the ERA‐CAPS I 3686 project of the Austrian Science Fund. We acknowledge support from the European Union's Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC‐XS)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling

  • Bradbury Lobato, Melissa
  • Castellví Vives, Josep
  • Mendez Fernández, Olga
  • Sánchez Iglesias, José Luis
  • Perez Benavente, Maria Asuncion
  • Gil Moreno, Antonio
  • Borràs, Eva
  • Sabidó, Eduard
  • Santamaria Margalef, Anna
Ovarian cancer; Proteomics, Cáncer de ovarios: Proteómica, Càncer d'ovaris; Proteòmica, Despite recent advances in the management of BRCA1 mutated high-grade serous ovarian cancer (HGSC), the physiology of these tumors remains poorly understood. Here we provide a comprehensive molecular understanding of the signaling processes that drive HGSC pathogenesis with the addition of valuable ubiquitination profiling, and their dependency on BRCA1 mutation-state directly in patient-derived tissues. Using a multilayered proteomic approach, we show the tight coordination between the ubiquitination and phosphorylation regulatory layers and their role in key cellular processes related to BRCA1-dependent HGSC pathogenesis. In addition, we identify key bridging proteins, kinase activity, and post-translational modifications responsible for molding distinct cancer phenotypes, thus providing new opportunities for therapeutic intervention, and ultimately advance towards a more personalized patient care., This work was supported by the PhD4MD collaborative research program between the Vall d’Hebron Research Institute (VHIR) and the Centre for Genomic Regulation (CRG). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, (CTQ2016-80364-P and “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208), and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595 and 2017SGR1661). This project has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC-XS). It has also been supported by grants from the Instituto Carlos III (PI15/00238, PI18/01017, PI21/00977), the Miguel Servet Program (CP13/00158 and CPII18/00027) and the Ministerio de Economía y Competitividad y Fondos FEDER (RTC-2015-3821-1). The authors are grateful to the team members of the Proteomics Unit at the Centre for Genomic Regulation, the Biomedical Research Group in Gynecology at the Vall d’Hebron Institute, the Gynecological Oncology Unit at the Vall d’Hebron Hospital and the Biomedical Research Group in Urology at the Vall d’Hebron Institute for their assistance.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mammalian TatD DNase domain containing 1 (TATDN1) is a proteostasis-responsive gene with roles in ventricular structure and neuromuscular function

  • Barés, Gisel
  • Beà Tàrrega, Aida
  • Sancho-Balsells, Anna
  • Valero, Juan Garcia
  • miro casas, elisabet
  • Ruiz Meana, Marisol
  • Aluja, David
  • Inserte, Javier
Cardiomyopathy; Motor control; Neurobehavior, Cardiomiopatía; Control motor; Neuroconducta, Cardiomiopatia; Control motor; Neuroconducta, The characterization of highly conserved but poorly understood genes often reveals unexpected biological roles, advancing our understanding of disease mechanisms. One such gene is Mammalian TatD DNase domain containing 1 (Tatdn1), the mammalian homolog of bacterial Twin-arginine translocation D (TatD), a protein proposed to have roles either in DNA degradation or protein quality control in unicellular organisms. Despite its association with different pathologies, including several cancer types and cardiovascular diseases, the role of TATDN1 in mammals remains unexplored. Here, we demonstrate that Tatdn1 encodes a cytoplasmic protein that does not participate in DNA degradation but is upregulated in cells under proteostasis stress. Tatdn1-deficient mice exhibit dysregulated expression of genes involved in membrane and extracellular protein biology, along with mild dilated cardiomyopathy and impaired motor coordination. These findings identify TATDN1 as a key player in cytosolic processes linked to protein homeostasis, with significant physiological implications for cardiac and neurological function., This research was funded by Ministerio de Ciencia, Innovación y Universidades, Gobierno de España, grant numbers PID2019-104509RB-I00 and PID2022-139965OB-100 to DS; Fundació La Marató TV3, grant number 20153810 to DS; AGAUR, Generalitat de Catalunya, grant number 2014-SGR-1609 to DS and JXC; GB holds a contract from the University of Lleida; AB holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida. SGC is the recipient of a FI Joan Oró contract from the Generalitat de Catalunya and co-financed by the European Social Fund Plus (FSE+) (AGAUR_2024_FI-1_00908) and AG is a Ramón y Cajal fellow (RYC-2016-19466) supported by a grant from Ministerio de Ciencia, Innovación y Universidades (PID2021-122258OB-I00). We thank the personnel of the University of Lleida Experimental Animal Service and Roser Pané for their technical assistance at IRBLleida and Ana López (María de Maeztu Unit of Excellence, Institute of Neurosciences, University of Barcelona, MDM-2017-0729, Ministerio de Ciencia, Innovación y Universidades) for technical support. We thank Dimitri Shcherbakov (Institut fur Medizinische Mikrobiologie, Universitat Zurich, Switzerland.) for his kind gift of HEK293 WT and RPS9 D95N mutant cells. JI and MRM are funded by Instituto de Salud Carlos III (ISCIII) (PI19-01196 and PI20-01681), CIBER-CV, and the European Regional Development Fundings (ERDF-FEDER). Work at The Novo Nordisk Foundation Center for Protein Research (CPR) is funded in part by a generous donation from the Novo Nordisk Foundation (Grant number NNF14CC0001) and from the European Union's Horizon 2020 research and innovation program under grant agreement EPIC-XS-823839.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

PDBe-KB: collaboratively defining the biological context of structural data

  • Varadi, Mihaly
  • Radusky, Leandro
  • Serrano Pubull, Luis, 1982-
  • Velankar, Sameer
  • PDBe-KB consortium
The Protein Data Bank in Europe - Knowledge Base (PDBe-KB, https://pdbe-kb.org) is an open collaboration between world-leading specialist data resources contributing functional and biophysical annotations derived from or relevant to the Protein Data Bank (PDB). The goal of PDBe-KB is to place macromolecular structure data in their biological context by developing standardised data exchange formats and integrating functional annotations from the contributing partner resources into a knowledge graph that can provide valuable biological insights. Since we described PDBe-KB in 2019, there have been significant improvements in the variety of available annotation data sets and user functionality. Here, we provide an overview of the consortium, highlighting the addition of annotations such as predicted covalent binders, phosphorylation sites, effects of mutations on the protein structure and energetic local frustration. In addition, we describe a library of reusable web-based visualisation components and introduce new features such as a bulk download data service and a novel superposition service that generates clusters of superposed protein chains weekly for the whole PDB archive., Funding: ELIXIR [IDP implementation study]; Biotechnology and Biological Sciences Research Council via the 3D-Gateway [BB/T01959X/1]; FunPDBe [BB/P024351/1]; J.D. acknowledges support from the Ministry of Education, Youth and Sport of the Czech Republic [INBIO CZ.02.1.01/0.0/0.0/16_026/0008451]; R.S., K.B. and J.D. also acknowledge support from the Ministry of Education, Youth and Sport of the Czech Republic [ELIXIR-CZ LM2018131]; L.M. acknowledges support from the European Union's Horizon 2020 Programme (H2020-INFRAIA-2018-1) [823839]; Research Foundation Flanders (FWO) [G032816N, G042518N, G028821N]; W.V. acknowledges support from the Research Foundation Flanders (FWO) [G032816N, G028821N]; A.R. acknowledges support from the Fondazione Cassa Di Risparmio di Firenze [24316]; European Commission [101017567]; M.H.C. acknowledges the AIRC project to MHC [IG 23539]; J.F.-R. acknowledges support from the Spanish Ministry of Science and Innovation [PID2019-110167RB-I00]; N.R. acknowledges support from the Norwegian Research Council (Norges Forskningsråd) [288008]; E.D.L. acknowledges support from the European Union's Horizon 2020 research and innovation programme [819318]; M.J.E.S. acknowledges support from the Wellcome Trust [104955/Z/14/Z, 218242/Z/19/Z]. Funding for open access charge: Biotechnology and Biological Sciences Research Council grant [BB/T01959X/1]; Wellcome Trust [104955/Z/14/Z and 218242/Z/19/Z]
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management

  • Bradbury Lobato, Melissa
  • Vilar Sánchez, Marta Esther
  • Castellví Vives, Josep
  • Sánchez Iglesias, José Luis
  • Perez Benavente, Maria Asuncion
  • Gil Moreno, Antonio
  • Borràs, Eva
  • Sabidó, Eduard
  • Santamaria Margalef, Anna
Biomarker; Prediction; Proteomics, Biomarcador; Predicción; Proteómica, Biomarcador; Predicció; Proteòmica, Background High-grade serous carcinoma (HGSC) is the most common and deadly subtype of ovarian cancer. Although most patients will initially respond to first-line treatment with a combination of surgery and platinum-based chemotherapy, up to a quarter will be resistant to treatment. We aimed to identify a new strategy to improve HGSC patient management at the time of cancer diagnosis (HGSC-1LTR). Methods A total of 109 ready-available formalin-fixed paraffin-embedded HGSC tissues obtained at the time of HGSC diagnosis were selected for proteomic analysis. Clinical data, treatment approach and outcomes were collected for all patients. An initial discovery cohort (n = 21) were divided into chemoresistant and chemosensitive groups and evaluated using discovery mass-spectrometry (MS)-based proteomics. Proteins showing differential abundance between groups were verified in a verification cohort (n = 88) using targeted MS-based proteomics. A logistic regression model was used to select those proteins able to correctly classify patients into chemoresistant and chemosensitive. The classification performance of the protein and clinical data combinations were assessed through the generation of receiver operating characteristic (ROC) curves. Results Using the HGSC-1LTR strategy we have identified a molecular signature (TKT, LAMC1 and FUCO) that combined with ready available clinical data (patients’ age, menopausal status, serum CA125 levels, and treatment approach) is able to predict patient response to first-line treatment with an AUC: 0.82 (95% CI 0.72–0.92). Conclusions We have established a new strategy that combines molecular and clinical parameters to predict the response to first-line treatment in HGSC patients (HGSC-1LTR). This strategy can allow the identification of chemoresistance at the time of diagnosis providing the optimization of therapeutic decision making and the evaluation of alternative treatment strategies. Thus, advancing towards the improvement of patient outcome and the individualization of HGSC patients’ care., This work was supported by the PhD4MD collaborative research program between the Vall d’Hebron Research Institute (VHIR) and the Centre for Genomic Regulation (CRG). It has been supported by grants from the Instituto Carlos III (PI18/01017), the Miguel Servet Program (CPII18/00027) and the Ministerio de Economía y Competitividad y Fondos FEDER (RTC-2015-3821-1 to AS and CTQ2016-80364-P to ES). This project has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC-XS).The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595 and 2017SGR1661). We also acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme / Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Beauveria bassiana rewires molecular mechanisms related to growth and defense in tomato

  • Proietti, Silvia
  • Falconieri, Gaia Salvatore
  • Bertini, Laura
  • Pascale, Alberto
  • Bizzarri, Elisabetta
  • Morales Sanfrutos, Julia
  • Sabidó Aguadé, Eduard, 1981-
  • Ruocco, Michelina
  • Monti, Maurilia M.
  • Russo, Assunta
  • Dziurka, Kinga
  • Ceci, Marcello
  • Loreto, Francesco
  • Caruso, Carla
Plant roots can exploit beneficial associations with soil-inhabiting microbes, promoting growth and expanding the immune capacity of the host plant. In this work, we aimed to provide new information on changes occurring in tomato interacting with the beneficial fungus Beauveria bassiana. The tomato leaf proteome revealed perturbed molecular pathways during the establishment of the plant-fungus relationship. In the early stages of colonization (5-7 d), proteins related to defense responses to the fungus were down-regulated and proteins related to calcium transport were up-regulated. At later time points (12-19 d after colonization), up-regulation of molecular pathways linked to protein/amino acid turnover and to biosynthesis of energy compounds suggests beneficial interaction enhancing plant growth and development. At the later stage, the profile of leaf hormones and related compounds was also investigated, highlighting up-regulation of those related to plant growth and defense. Finally, B. bassiana colonization was found to improve plant resistance to Botrytis cinerea, impacting plant oxidative damage. Overall, our findings further expand current knowledge on the possible mechanisms underlying the beneficial role of B. bassiana in tomato plants., This work was supported by Ministero dell' Università e della Ricerca (MUR) - [PRIN Project no. 2017JLN833_005]: “Plant multitROphic interactions for bioinspired Strategies of PEst ConTrol (PROSPECT)”. The work of Alberto Pascale was supported by Marie Skłodowska‐Curie Individual Fellowship MSCA-IF-2019 [MetaFun, grant agreement: 893366]. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). This project was supported by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union. We also acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Programme/Generalitat de Catalunya, and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya (2017SGR595).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Chromatin-bound proteome profiling by genome capture

  • Aranda Aragón, Sergio
  • Borràs, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Di Croce, Luciano
De novo identification of chromatin interactors can reveal unexpected pathways relevant to physiology and human disease. Inspired by the DNA mediated chromatin pull-down (Dm-ChP) technology (also known as iPOND [isolation of proteins on nascent DNA]) for the proteomic characterization of nascent DNA, we have recently reported a new experimental protocol that allows for the identification of proteins on total DNA (iPOTD) for bulk chromatome profiling and de novo identification of chromatin-bound proteins. Here, we detail a step-by-step protocol to survey the cellular chromatin-bound proteome in a simple, robust, and unbiased manner. For complete details on the use and execution of this protocol, please refer to Aranda et al. (2019)., The Proteomics Unit is supported by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union. The Di Croce Laboratory is supported by grants from the Spanish Ministerio de Educación y Ciencia (BFU2016-75008-P) and by AGAUR.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Polyamine-dependent metabolic shielding regulates alternative splicing

  • Zabala-Letona, Amaia
  • Rogalska, Malgorzata
  • Valcárcel, J. (Juan)
  • Carracedo, Arkaitz
Metabolites are central to cellular homeostasis. Although much emphasis has been placed on their relevance to meet energetic and biosynthetic demands, metabolic intermediates also function as signalling molecules. Here we show that polyamines, small polycations that are critical to cellular homeostasis1-3, regulate the process of alternative pre-mRNA splicing. We find that inhibition of polyamine synthesis increases phosphorylation of spliceosomal proteins, concomitant with perturbation of alternative splicing in cells and tissues. Mechanistically, molecular modelling combined with biochemical assays revealed that polyamines bind to acidic phosphorylatable motifs in splicing factors of the U2 small nuclear ribonucleoprotein SF3 subcomplex, thus preventing the action of upstream kinases. We refer to this molecular process by which polyamines regulate protein phosphorylation as metabolic shielding., The work of A.C. is supported by the MICIU (PID2022-141553OB-I0 (FEDER/EU), BBVA foundation Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261), Fundación Cris Contra el Cáncer (PR_EX_2021-22), Severo Ochoa Excellence Accreditation (CEX2021-001136-S), Fundación AECC (Excelencia 2024 call, Premetacan—EPAEC246710BIO), Fundación Occident, Astrazeneca Foundation (Young Oncologist award), Vencer el Cáncer Foundation, Mondravember, iDIFFER Network of Excellence (RED2022-134792-T; RED2024-153635-T), and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and ISCIII. A.Z.-L. is supported by AECC (INVES223210ZABA). M.P.-V. was supported by a Basque Government PhD training fellowship and CIBER. B.M.-L. and M.A.-C. were supported by FPI fellowships (MCIU). M.F.-E. was supported by Basque Government PhD training fellowship. A. Ercilla is supported by a Juan de la Cierva Incorporación fellowship from the MCIN/AEI /10.13039/501100011033. L.B.-B. was supported by the AECC Foundation (POSTD19048BOZA). M.Z. and R.A.S. are supported by the National Science Centre, Poland (grant no. 2020/38/E/ST4/00250). I.M. is supported by Fundación Cris Contra el Cáncer (PR_TPD_2020-19) and a Ramón y Cajal contract (RYC2023-044682-I) funded by the MCIU. G.J.-O. was funded by the MICIU (PID2021-125946OB-I00 and PDC2022-133725-C22). F.P. was funded by the MICIU (IJC2020-045506-I) and RYC (RYC2022-036457-I). F.J.B. was funded by PID2023-147699OB-I00 grant from AEI- /10.13039/501100011033. The work of A.R. is partially supported by the Basque Department of Industry, Tourism and Trade (Elkartek). The laboratory of J.M. is supported by the European Union Horizon 2020 programme INFRAIA project EPIC-XS (project 823839). S.C. and R.J.M. were supported by grants from the NOMIS Foundation and Geistlich-Stucki Stiftung. R.B. and J.D.S. were funded by PID2020-114178GB-I00 and PID2023-147399NB-I00 (MINECO /MICINN/FEDER, EU). E.B. is supported by the PID2022-141556OB-I00 (FEDER/EU) and RED2022-134407-T). A. Efeyan is funded by grant PID2022-136413OB-I00. The laboratory of J.M.L. is funded by the MICIU (PID2022-136391OB-I00). The work of L.F. was supported by Memorial Sloan Cancer Center Support Grant P30CA008748. The work from R.J.M. in this publication is based on work from COST Action Translational control in Cancer European Network (TRANSLACORE) CA21154 supported by COST (European Cooperation in Science and Technology). M.D.H. was supported by a US Department of Defense Team Translational Science Award (CA170257).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dissecting sexual dimorphism in aortic valve stenosis by proteomics

  • Grego, Ana
  • Sousa-Mendes, Cláudia
  • Martins, Diana
  • Sousa, Carla
  • Ferreira, Ana Filipa
  • Saraiva, Francisca
  • Alves, Inês
  • Espadas, Guadalupe
  • Miranda, Isabel
  • Leite-Moreira, Adelino
  • Sabidó Aguadé, Eduard, 1981-
  • Barros, António S.
  • Gavina, Cristina
  • Vitorino, Rui
  • Falcão-Pires, Inês
  • Nogueira-Ferreira, Rita
  • Trindade, Fábio
Background: The treatment of aortic valve stenosis (AVS) remains limited to aortic valve replacement (AVR). No pharmacotherapy has yet proven efficacious, and its development is challenged by sexual dimorphism. Women display extensive valve fibrosis, and men present remarkably higher valve calcification. To accelerate the development of sex-personalised therapies, deeper molecular insights are needed. Hence, we aimed to characterise AVS sexual dimorphism using proteomics. Methods: Fifty surgically excised valves (50% women) were homogenised, and the proteins were quantified by LC-MS/MS. The influence of differentially expressed proteins (DEPs) in sexual dimorphism was appraised using bioinformatics. DEPs were validated using immunohistochemistry, qRT-PCR and ELISA, with 30 additional valves. Results: We quantified ~ 4,000 proteins and 76 DEPs between sexes. CD163, CD74, and NADPH oxidase-2 (NOX2) were more abundant in men's valves and central in a protein-protein interaction network. Functional enrichment analysis (FEA) supported increased lipoprotein binding and macrophage activation in men's valves, confirmed by increased CD74 + cell infiltration (immunohistochemistry). Aminopeptidase N, coagulation factor XIII, and metalloreductase STEAP4 were more abundant in men's valves at the transcript and protein levels. FEA indicated a women-specific dysregulation of spliceosomal proteins that may dictate a pro-fibrotic phenotype, which was observed histologically. A higher glutathione peroxidase-1/NOX2 ratio (ELISA) was found in women, suggesting increased protection against oxidative stress. Conclusions: Proteomics confirms sexual dimorphism in AVS. Women displayed a higher degree of fibrotic remodelling, whereas men displayed greater immune cell infiltration and were less protected from oxidation, favouring calcification. Proteomics identified putative targets for a sex-personalised AVS modulation., This work was supported by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union; Sigma Xi, The Scientific Research Honor Society (NC, USA), grant number G20230315-4761, and by national funds through FCT (Fundação para a Ciência e a Tecnologia, I.P.), within the scope of the Cardiovascular R&D Center (UIDB/00051/2020, UIDP/00051/2020) and RISE (LA/P/0053/2020). A.G. was supported by a fellowship grant from the SEXDIFEND project (2022.04344.PTDC, https://doi.org/10.54499/2022.04344.PTDC). I.A. and D.M. are supported by doctoral fellowships by FCT (grants 2022.11324.BD and 2021.06947.BD, respectively). R.N.F. is supported by FCT through the research contract CEECIND/03935/2021 under the CEEC Individual 2021 (https://doi.org/10.54499/2021.03935.CEECIND/CP1685/CT0001). F.T. was supported by a postdoctoral research grant from FCT through the Cardiovascular R&D Centre (UnIC, UIDP/00051/2020). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). G.E. and E.S. are supported by the Spanish Ministry of Science and Innovation (“Centro de Excelencia Severo Ochoa 2013–2017”, SEV-2012-0208), and by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2021SGR01225). G.E. and E.S. are also supported by the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, the CERCA Programme from Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Isotopologue multipoint calibration for proteomics biomarker quantification in clinical practice

  • Chiva, Cristina
  • Pastor, Olga
  • Trilla Fuertes, Lucía
  • Gámez Pozo, Angelo
  • Fresno Vara, Juan Ángel
  • Sabidó Aguadé, Eduard, 1981-
Targeted proteomics has become the method of choice for biomarker validation in human biopsies due to its high sensitivity, reproducibility, accuracy, and precision. However, for targeted proteomics to be transferred to clinical routine there is the need to reduce its complexity, make its procedures simpler, increase its throughput, and improve its analytical performance. Here we present the Isotopologue Multipoint Calibration (ImCal) quantification strategy, which uses a mix of isotopologue peptides to generate internal multipoint calibration curves for each individual sample and to accurately quantify biomarker peptides in clinical applications without the need of expert supervision. ImCal relies on the use of five different isotopically-labelled peptides of different nominal mass mixed at different concentrations to be used as an internal calibration curve for each endogenous peptide. The use of internal multipoint calibration curves is well-suited for the generation of ready-to-use biomarker kits for clinical applications as it is compatible with both high- and low-resolution mass spectrometers and different levels of endogenous peptide, it eliminates the need for blank matrixes required in external curves, it allows the evaluation of matrix effects and the valid quantification range in each individual sample, and it does not require expert adjustment. We used the ImCal method to quantify HER2 in 35 breast cancer formalin-fixed paraffin-embedded patient samples, revealing a high degree of heterogeneity among patients, which contrasts with the homogeneous immunohistochemistry patient classification. Our work illustrates how an improvement of mass spectrometry methods for biomarker quantification can provide fine-grain patient stratification, and thus better disease diagnostic and prognosis., The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by Grant PT17/0019/0021 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, “Centro de Excelencia Severo Ochoa 2013–2017”, Grant SEV-2012-0208, and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” Grant (2017SGR595). This project has also received funding from the European Union’s Horizon 2020 research and innovation program under Grant Agreement No. 823839 (EPIC-XS). L.T.-F. is supported by Spanish Economy and Competitiveness Ministry (Grant DI-15-07614). The Molecular Oncology and Pathology Lab is supported by Instituto de Salud Carlos III, Spanish Economy and Competitiveness Ministry, Spain, and cofunded by the FEDER program, “Una forma de hacer Europa” (Grant PI15/01310).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Claudin-6 mediates an embryonic stem cell-driven antitumor response against breast cancer

  • Correia, Magda
  • Tavares-Marcos, Carlota
  • Pessoa, João
  • Casanova, Miguel
  • Cavadas, Bruno
  • Vitorino, Rui
  • Tavares e Silva, Júlia
  • Mateus, Francisca
  • Espadas, Guadalupe
  • Pinheiro, Mariana
  • Alves-Vale, Catarina
  • Sabidó Aguadé, Eduard, 1981-
  • Neves, Bruno
  • Nóbrega-Pereira, Sandrina
  • Bernardes de Jesus, Bruno
Stem cells are emerging sources of antigens for cancer immunotherapy. Here, we used TNG-A mouse embryonic stem cells to trigger an anticancer response against tumors derived from E0771 mouse breast cancer cells, possibly mediated by the mouse immune system. TNG-A cells were cultured in the presence or absence of two specific kinase inhibitors. While the inhibitors preserved TNG-A pluripotency, their removal altered the morphology, transcriptome, and proteome of TNG-A cells, increasing their similarities with E0771 cancer cells. Double pre-exposure by subcutaneous injection of TNG-A cells followed by E0771 implantation drastically decreased E0771-derived tumor size in mice. Serum cytokine quantifications suggested a transient immune reaction associated with tumor regression. Nevertheless, pre-exposure to TNG-A cells impaired for the tight junction protein Claudin 6 failed to decrease tumor size. Our findings demonstrate the anti-tumor effects of embryonic stem cells and anticipate their potential as an allogenic source for cancer immunotherapy., This work was supported by Fundação para a Ciência e a Tecnologia (FCT) EXPL/BIA-CEL/0358/2021 and LISBOA-01-0145-FEDER-028534, project co-funded by the European Regional Development Fund (FEDER) through the POR Lisboa 2020—Programa Operacional Regional de Lisboa, Portugal 2020, and by FCT, through the project 2022.01199.PTDC DOI:10.54499/2022.01199. PTDC and Institute of Biomedicine—iBiMED (UIDP/04501/2020, UIDB/04501/2020 and UID 4501 - Institute of Biomedicine). B.C. is supported by the Junior Researcher grant CEECINST/00123/2021/CP1772/CT0001. S.N.-P. received funding from FCT CEECIND Program (2020.00355.CEECIND). M.C. was a recipient of an individual FCT predoctoral fellowship (UI/BD/151373/2021), Portugal. C.T.M. is funded by an individual predoctoral fellowship (BI/REIT/10332/2024), Portugal. This project has also received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC-XS). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Program/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Decoding protein methylation function with thermal stability analysis

  • Sayago, Cristina
  • Sánchez-Wandelmer, Jana
  • Garcia-Martinez, Fernando
  • Hurtado, Begoña
  • Lafarga, Vanesa
  • Prieto, Patricia
Methylation; Proteomics, Metilació; Proteòmica, Metilación; Proteómica, Protein methylation is an important modification beyond epigenetics. However, systems analyses of protein methylation lag behind compared to other modifications. Recently, thermal stability analyses have been developed which provide a proxy of a protein functional status. Here, we show that molecular and functional events closely linked to protein methylation can be revealed by the analysis of thermal stability. Using mouse embryonic stem cells as a model, we show that Prmt5 regulates mRNA binding proteins that are enriched in intrinsically disordered regions and involved in liquid-liquid phase separation mechanisms, including the formation of stress granules. Moreover, we reveal a non-canonical function of Ezh2 in mitotic chromosomes and the perichromosomal layer, and identify Mki67 as a putative Ezh2 substrate. Our approach provides an opportunity to systematically explore protein methylation function and represents a rich resource for understanding its role in pluripotency., We thank all members of the CNIO Proteomics Unit for discussions, the CNIO Flow Cytometry Unit for flow cytometry support, Cyan Lynch for sharing reagents and Ana Martinez-Val for support with data analysis. This work was supported by SAF2016-74962-R (MINECO) and the European Union Horizon 2020 program INFRAIA project EPIC-XS (project 823839). The CNIO Proteomics Unit belongs to ProteoRed, PRB3- ISCIII, supported by grant PT17/0019/0005. J.M. is supported by the Ikerbasque Programme, Basque Foundation for Science. O.F-C. is supported by grants from the Spanish Ministry of Science, Innovation and Universities (PID2021-128722OB-I00, co-financed with European FEDER funds) and the Spanish Association Against Cancer (AECC; PROYE20101FERN). M.M. lab was supported by grants from MINECO (PID2021-128726 and PDC2022-133408-I00), and Comunidad de Madrid (Y2020/BIO-6519 and S2022/BMD-7437).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling

  • Bradbury Lobato, Melissa, 1983-
  • Borràs, Eva
  • Castellví, Josep
  • Méndez, Olga
  • Sánchez-Iglesias, José Luis
  • Pérez-Benavente, Assumpció
  • Gil-Moreno, Antonio
  • Sabidó Aguadé, Eduard, 1981-
  • Santamaria, Anna
Despite recent advances in the management of BRCA1 mutated high-grade serous ovarian cancer (HGSC), the physiology of these tumors remains poorly understood. Here we provide a comprehensive molecular understanding of the signaling processes that drive HGSC pathogenesis with the addition of valuable ubiquitination profiling, and their dependency on BRCA1 mutation-state directly in patient-derived tissues. Using a multilayered proteomic approach, we show the tight coordination between the ubiquitination and phosphorylation regulatory layers and their role in key cellular processes related to BRCA1-dependent HGSC pathogenesis. In addition, we identify key bridging proteins, kinase activity, and post-translational modifications responsible for molding distinct cancer phenotypes, thus providing new opportunities for therapeutic intervention, and ultimately advance towards a more personalized patient care., This work was supported by the PhD4MD collaborative research program between the Vall d’Hebron Research Institute (VHIR) and the Centre for Genomic Regulation (CRG). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, (CTQ2016-80364-P and “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208), and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595 and 2017SGR1661). This project has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC-XS). It has also been supported by grants from the Instituto Carlos III (PI15/00238, PI18/01017, PI21/00977), the Miguel Servet Program (CP13/00158 and CPII18/00027) and the Ministerio de Economía y Competitividad y Fondos FEDER (RTC-2015-3821-1)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

MassIVE.quant: a community resource of quantitative mass spectrometry-based proteomics datasets

  • Choi, Meena
  • Chiva, Cristina
  • Sabidó Aguadé, Eduard, 1981-
  • Vitek, Olga
MassIVE.quant is a repository infrastructure and data resource for reproducible quantitative mass spectrometry-based proteomics, which is compatible with all mass spectrometry data acquisition types and computational analysis tools. A branch structure enables MassIVE.quant to systematically store raw experimental data, metadata of the experimental design, scripts of the quantitative analysis workflow, intermediate input and output files, as well as alternative reanalyses of the same dataset., This work was supported in part by NSF CAREER award no. DBI-1054826, grant no. NSF DBI-1759736 and the Chan-Zuckerberg foundation to O.V., grant no. NIH-NLM 1R01LM013115 to N.B. and O.V., NSF award no. ABI 1759980, NIH award nos. P41GM103484 and R24GM127667 to N.B. and the Personalized Health and Related Technologies (grant no. PHRT 0-21411-18) strategic focus area of ETH to B.W. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium that is supported by grant no. PT17/0019 of the PE I+D+i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, ‘Centro de Excelencia Severo Ochoa 2013–2017’, SEV-2012–0208 and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya (grant no. 2017SGR595). This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 823839 (EPIC-XS). Y.P.-R. acknowledges the Wellcome Trust (grant no. 208391/Z/17/Z).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

QCloud2: an improved cloud-based quality-control system for mass-spectrometry-based proteomics laboratories

  • Olivella, Roger
  • Chiva, Cristina
  • Serret, Marc
  • Mancera, Daniel
  • Cozzuto, Luca
  • Hermoso Pulido, Antonio
  • Borràs, Eva
  • Espadas, Guadalupe
  • Morales Sanfrutos, Julia
  • Pastor, Olga
  • Solé, Amanda
  • Ponomarenko, Julia
  • Sabidó Aguadé, Eduard, 1981-
QCloud is a cloud-based system to support proteomics laboratories in daily quality assessment using a user-friendly interface, easy setup, and automated data processing. Since its release, QCloud has facilitated automated quality control for proteomics experiments in many laboratories. QCloud provides a quick and effortless evaluation of instrument performance that helps to overcome many analytical challenges derived from clinical and translational research. Here we present an improved version of the system, QCloud2. This new version includes enhancements in the scalability and reproducibility of the quality-control pipelines, and it features an improved front end for data visualization, user management, and chart annotation. The QCloud2 system also includes programmatic access and a standalone local version., The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is a member of the ProteoRed PRB3 consortium, which is supported by grant PT17/0019 of the PE I+D+i 2013−2016 from the Instituto de Salud Carlos III (ISCIII), ERDF, and “Secretaria d’Universitats i Recerca del Departament d’Econòmia i Coneixement de la Generalitat de Catalunya” (2017SGR595). This project was supported by EPIC-XS, project number 823839, funded by the Horizon 2020 Programme of the European Union. We also acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme from Generalitat de Catalunya
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Use of linear ion traps in data-independent acquisition methods benefits low-input proteomics

  • Borràs, Eva
  • Pastor, Olga
  • Sabidó Aguadé, Eduard, 1981-
The need for a better understanding of cellular heterogeneity has pushed mass spectrometry technologies to the analysis of single-cell and single-cell-type proteomes, although several challenges still limit their widespread implementation. Among the efforts toward single-cell and low-input analyses, there is the adoption of data-independent acquisition methods to increase analytical sensitivity. Here, we revisited the use of linear ion traps mass analyzers in data-independent acquisition methods and demonstrate their benefits to boost peptide and protein identifications in low-input proteomes., Funding: the CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is member of ProteoRed PRB3 consortium which is supported by Grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII), ERDF, and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). This project was supported by EPIC-XS, Project Number 823839, funded by the Horizon 2020 programme of the European Union. We also acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Decoding protein methylation function with thermal stability analysis

  • Sayago, Cristina
  • Sánchez-Wandelmer, Jana
  • Garcia-Martinez, Fernando
  • Hurtado, Begoña
  • Lafarga, Vanesa
  • Prieto, Patricia
Methylation; Proteomics, Metilació; Proteòmica, Metilación; Proteómica, Protein methylation is an important modification beyond epigenetics. However, systems analyses of protein methylation lag behind compared to other modifications. Recently, thermal stability analyses have been developed which provide a proxy of a protein functional status. Here, we show that molecular and functional events closely linked to protein methylation can be revealed by the analysis of thermal stability. Using mouse embryonic stem cells as a model, we show that Prmt5 regulates mRNA binding proteins that are enriched in intrinsically disordered regions and involved in liquid-liquid phase separation mechanisms, including the formation of stress granules. Moreover, we reveal a non-canonical function of Ezh2 in mitotic chromosomes and the perichromosomal layer, and identify Mki67 as a putative Ezh2 substrate. Our approach provides an opportunity to systematically explore protein methylation function and represents a rich resource for understanding its role in pluripotency., We thank all members of the CNIO Proteomics Unit for discussions, the CNIO Flow Cytometry Unit for flow cytometry support, Cyan Lynch for sharing reagents and Ana Martinez-Val for support with data analysis. This work was supported by SAF2016-74962-R (MINECO) and the European Union Horizon 2020 program INFRAIA project EPIC-XS (project 823839). The CNIO Proteomics Unit belongs to ProteoRed, PRB3- ISCIII, supported by grant PT17/0019/0005. J.M. is supported by the Ikerbasque Programme, Basque Foundation for Science. O.F-C. is supported by grants from the Spanish Ministry of Science, Innovation and Universities (PID2021-128722OB-I00, co-financed with European FEDER funds) and the Spanish Association Against Cancer (AECC; PROYE20101FERN). M.M. lab was supported by grants from MINECO (PID2021-128726 and PDC2022-133408-I00), and Comunidad de Madrid (Y2020/BIO-6519 and S2022/BMD-7437).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling

  • Bradbury Lobato, Melissa
  • Castellví Vives, Josep
  • Mendez Fernández, Olga
  • Sánchez Iglesias, José Luis
  • Perez Benavente, Maria Asuncion
  • Gil Moreno, Antonio
  • Borràs, Eva
  • Sabidó, Eduard
  • Santamaria Margalef, Anna
Ovarian cancer; Proteomics, Cáncer de ovarios: Proteómica, Càncer d'ovaris; Proteòmica, Despite recent advances in the management of BRCA1 mutated high-grade serous ovarian cancer (HGSC), the physiology of these tumors remains poorly understood. Here we provide a comprehensive molecular understanding of the signaling processes that drive HGSC pathogenesis with the addition of valuable ubiquitination profiling, and their dependency on BRCA1 mutation-state directly in patient-derived tissues. Using a multilayered proteomic approach, we show the tight coordination between the ubiquitination and phosphorylation regulatory layers and their role in key cellular processes related to BRCA1-dependent HGSC pathogenesis. In addition, we identify key bridging proteins, kinase activity, and post-translational modifications responsible for molding distinct cancer phenotypes, thus providing new opportunities for therapeutic intervention, and ultimately advance towards a more personalized patient care., This work was supported by the PhD4MD collaborative research program between the Vall d’Hebron Research Institute (VHIR) and the Centre for Genomic Regulation (CRG). The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is a member of the ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I+D+i 2013-2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. We acknowledge support from the Spanish Ministry of Science, Innovation and Universities, (CTQ2016-80364-P and “Centro de Excelencia Severo Ochoa 2013-2017”, SEV-2012-0208), and “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595 and 2017SGR1661). This project has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC-XS). It has also been supported by grants from the Instituto Carlos III (PI15/00238, PI18/01017, PI21/00977), the Miguel Servet Program (CP13/00158 and CPII18/00027) and the Ministerio de Economía y Competitividad y Fondos FEDER (RTC-2015-3821-1). The authors are grateful to the team members of the Proteomics Unit at the Centre for Genomic Regulation, the Biomedical Research Group in Gynecology at the Vall d’Hebron Institute, the Gynecological Oncology Unit at the Vall d’Hebron Hospital and the Biomedical Research Group in Urology at the Vall d’Hebron Institute for their assistance.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Mammalian TatD DNase domain containing 1 (TATDN1) is a proteostasis-responsive gene with roles in ventricular structure and neuromuscular function

  • Barés, Gisel
  • Beà Tàrrega, Aida
  • Sancho-Balsells, Anna
  • Valero, Juan Garcia
  • miro casas, elisabet
  • Ruiz Meana, Marisol
  • Aluja, David
  • Inserte, Javier
Cardiomyopathy; Motor control; Neurobehavior, Cardiomiopatía; Control motor; Neuroconducta, Cardiomiopatia; Control motor; Neuroconducta, The characterization of highly conserved but poorly understood genes often reveals unexpected biological roles, advancing our understanding of disease mechanisms. One such gene is Mammalian TatD DNase domain containing 1 (Tatdn1), the mammalian homolog of bacterial Twin-arginine translocation D (TatD), a protein proposed to have roles either in DNA degradation or protein quality control in unicellular organisms. Despite its association with different pathologies, including several cancer types and cardiovascular diseases, the role of TATDN1 in mammals remains unexplored. Here, we demonstrate that Tatdn1 encodes a cytoplasmic protein that does not participate in DNA degradation but is upregulated in cells under proteostasis stress. Tatdn1-deficient mice exhibit dysregulated expression of genes involved in membrane and extracellular protein biology, along with mild dilated cardiomyopathy and impaired motor coordination. These findings identify TATDN1 as a key player in cytosolic processes linked to protein homeostasis, with significant physiological implications for cardiac and neurological function., This research was funded by Ministerio de Ciencia, Innovación y Universidades, Gobierno de España, grant numbers PID2019-104509RB-I00 and PID2022-139965OB-100 to DS; Fundació La Marató TV3, grant number 20153810 to DS; AGAUR, Generalitat de Catalunya, grant number 2014-SGR-1609 to DS and JXC; GB holds a contract from the University of Lleida; AB holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida. SGC is the recipient of a FI Joan Oró contract from the Generalitat de Catalunya and co-financed by the European Social Fund Plus (FSE+) (AGAUR_2024_FI-1_00908) and AG is a Ramón y Cajal fellow (RYC-2016-19466) supported by a grant from Ministerio de Ciencia, Innovación y Universidades (PID2021-122258OB-I00). We thank the personnel of the University of Lleida Experimental Animal Service and Roser Pané for their technical assistance at IRBLleida and Ana López (María de Maeztu Unit of Excellence, Institute of Neurosciences, University of Barcelona, MDM-2017-0729, Ministerio de Ciencia, Innovación y Universidades) for technical support. We thank Dimitri Shcherbakov (Institut fur Medizinische Mikrobiologie, Universitat Zurich, Switzerland.) for his kind gift of HEK293 WT and RPS9 D95N mutant cells. JI and MRM are funded by Instituto de Salud Carlos III (ISCIII) (PI19-01196 and PI20-01681), CIBER-CV, and the European Regional Development Fundings (ERDF-FEDER). Work at The Novo Nordisk Foundation Center for Protein Research (CPR) is funded in part by a generous donation from the Novo Nordisk Foundation (Grant number NNF14CC0001) and from the European Union's Horizon 2020 research and innovation program under grant agreement EPIC-XS-823839.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management

  • Bradbury Lobato, Melissa
  • Vilar Sánchez, Marta Esther
  • Castellví Vives, Josep
  • Sánchez Iglesias, José Luis
  • Perez Benavente, Maria Asuncion
  • Gil Moreno, Antonio
  • Borràs, Eva
  • Sabidó, Eduard
  • Santamaria Margalef, Anna
Biomarker; Prediction; Proteomics, Biomarcador; Predicción; Proteómica, Biomarcador; Predicció; Proteòmica, Background High-grade serous carcinoma (HGSC) is the most common and deadly subtype of ovarian cancer. Although most patients will initially respond to first-line treatment with a combination of surgery and platinum-based chemotherapy, up to a quarter will be resistant to treatment. We aimed to identify a new strategy to improve HGSC patient management at the time of cancer diagnosis (HGSC-1LTR). Methods A total of 109 ready-available formalin-fixed paraffin-embedded HGSC tissues obtained at the time of HGSC diagnosis were selected for proteomic analysis. Clinical data, treatment approach and outcomes were collected for all patients. An initial discovery cohort (n = 21) were divided into chemoresistant and chemosensitive groups and evaluated using discovery mass-spectrometry (MS)-based proteomics. Proteins showing differential abundance between groups were verified in a verification cohort (n = 88) using targeted MS-based proteomics. A logistic regression model was used to select those proteins able to correctly classify patients into chemoresistant and chemosensitive. The classification performance of the protein and clinical data combinations were assessed through the generation of receiver operating characteristic (ROC) curves. Results Using the HGSC-1LTR strategy we have identified a molecular signature (TKT, LAMC1 and FUCO) that combined with ready available clinical data (patients’ age, menopausal status, serum CA125 levels, and treatment approach) is able to predict patient response to first-line treatment with an AUC: 0.82 (95% CI 0.72–0.92). Conclusions We have established a new strategy that combines molecular and clinical parameters to predict the response to first-line treatment in HGSC patients (HGSC-1LTR). This strategy can allow the identification of chemoresistance at the time of diagnosis providing the optimization of therapeutic decision making and the evaluation of alternative treatment strategies. Thus, advancing towards the improvement of patient outcome and the individualization of HGSC patients’ care., This work was supported by the PhD4MD collaborative research program between the Vall d’Hebron Research Institute (VHIR) and the Centre for Genomic Regulation (CRG). It has been supported by grants from the Instituto Carlos III (PI18/01017), the Miguel Servet Program (CPII18/00027) and the Ministerio de Economía y Competitividad y Fondos FEDER (RTC-2015-3821-1 to AS and CTQ2016-80364-P to ES). This project has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 823839 (EPIC-XS).The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595 and 2017SGR1661). We also acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Programme / Generalitat de Catalunya.